

First Hit

L10: Entry 2 of 50

File: PGPB

Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040077965
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040077965 A1

TITLE: Method for diagnosis of helicobacter pylori infection

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hubbard, Todd W.	Lake Forrest Park	WA	US	
Putnam, David L.	Sammamish	WA	US	

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	COUNTRY	TYPE CODE
Photonic BioSystems, Inc.				02

APPL-NO: 10/ 294352 [PALM]
DATE FILED: November 13, 2002

RELATED-US-APPL-DATA:

Application is a non-provisional-of-provisional application 60/331275, filed November 13, 2001,

INT-CL: [07] A61 B 5/08, G01 N 33/497, G01 N 31/00

US-CL-PUBLISHED: 600/532; 073/023.3, 422/084
US-CL-CURRENT: 600/532; 422/84, 73/23.3

REPRESENTATIVE-FIGURES: 1B

ABSTRACT:

A rapid, non-invasive breath-test method and device for diagnosing the presence or absence of H. pylori in a subject without administration of isotopic tracers is described. The device consists of a highly sensitive colorimetric ammonia sensor placed in contact with sampled subject breath. The sensor is measured using appropriate reflection spectroscopy instrumentation. The breath-test method consists of measuring a basal ammonia level with the device, administering non-isotopic urea and continuing measurement of the ammonia content in a plurality of consecutive breaths. Diagnostic differences in breath ammonia are identified between H. pylori infected and uninfected individuals.

RELATED APPLICATIONS

[0001] This application claims the benefit of the filing of U.S. Ser. No. 60/331,275 entitled "Method for Diagnosis of Helicobacter Pylori Infection" filed

on Nov. 13, 2001, hereby incorporated by reference.

FILE ORDERING
order patent files results



Thursday
5/27/04
12:52:19 PM
WFO1003PR

Serial# 09/574734 File order accepted

Place another order

WEST Search History

DATE: Thursday, May 27, 2004

Hide?	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=AND</i>	
<input type="checkbox"/>	L1	meridian.asn.	297
<input type="checkbox"/>	L2	L1 and (stool or faecal or fecal or feces or faeces or excrement or (colonic near3 (contents or excreta or material)))	18
<input type="checkbox"/>	L3	L2 and (pylori or helicobacter or pylroi or pylrois or pyloris or pylorum or pyloridis or hpylori)	12
<input type="checkbox"/>	L4	L2 and (pylori or helicobacter or pylroi or pylrois or pyloris or pylorum or pyloridis or hpylori)	12
<input type="checkbox"/>	L5	(pylori or helicobacter or pylroi or pylrois or pyloris or pylorum or pyloridis or hpylori)	6774
<input type="checkbox"/>	L6	(stool or faecal or fecal or feces or faeces or excrement or (colonic near3 (contents or excreta or material)))	49714
<input type="checkbox"/>	L7	L6 same l5	162
<input type="checkbox"/>	L8	L7 not l1	151
<input type="checkbox"/>	L9	L8 and (hybridoma or monoclonal or mono-clonal or moab or mab or m-ab or mo-ab or antibodies or antibody)	108
<input type="checkbox"/>	L10	L8 same (hybridoma or monoclonal or mono-clonal or moab or mab or m-ab or mo-ab or antibodies or antibody)	50

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 2 through 50 of 50 returned.**

-
- ☐ 2. [20040077965](#). 13 Nov 02. 22 Apr 04. Method for diagnosis of helicobacter pylori infection. Hubbard, Todd W., et al. 600/532; 422/84 73/23.3 A61B005/08 G01N033/497 G01N031/00.
-
- ☐ 3. [20040044197](#). 27 Jun 03. 04 Mar 04. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy. Pandey, Ravindra K., et al. 540/140; C09B047/04.
-
- ☐ 4. [20040023316](#). 27 Apr 01. 05 Feb 04. New method for detecting acid-resistant microorganisms in the stool. Reiter, Christian, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 5. [20040019505](#). 21 Jul 03. 29 Jan 04. Personalized health communication system. Bowman, Bradley R., et al. 705/2; G06F017/60.
-
- ☐ 6. [20030224401](#). 19 Feb 03. 04 Dec 03. Proteins for helicobacter diagnosis. Barthold, Stephen, et al. 435/6; 435/227 435/252.3 435/320.1 435/69.3 435/7.32 530/388.26 536/23.2 C12Q001/68 G01N033/554 G01N033/569 C07H021/04 C12N009/78 C12P021/02 C12N001/21.
-
- ☐ 7. [20030148411](#). 22 Jan 03. 07 Aug 03. Method for detecting helicobacter pylori and heilmanii in fecal and salivary specimen and biopsy material. Armbruster, Franz Paul, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 8. [20030124633](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 9. [20030124632](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 10. [20030109813](#). 10 Dec 02. 12 Jun 03. Energy-activated targeted cancer therapy. Chen, James. 601/2; A61H001/00.
-
- ☐ 11. [20030104484](#). 31 Dec 02. 05 Jun 03. Materials and methods for detection and quantitation of an analyte. Cleaver, Brian D., et al. 435/7.1; G01N033/53.
-
- ☐ 12. [20020182600](#). 11 Apr 01. 05 Dec 02. Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques. Smith, Jack V.. 435/6; C12Q001/68.
-
- ☐ 13. [20020160428](#). 26 Apr 02. 31 Oct 02. Quantitative non-instrumental immunoassay and device using coloured particles. Sundrehagen, Erling. 435/7.9; 435/287.2 G01N033/53 G01N033/542 C12M001/34.
-
- ☐ 14. [20020142291](#). 13 Apr 01. 03 Oct 02. Positive detection lateral-flow apparatus and method for small and large analytes. Bauer, Jeffrey S., et al. 435/5; 435/287.2 435/345 435/7.1 436/518 C12M001/34 G01N033/543 C12Q001/70 G01N033/53 C12M003/00 C12N005/06 C12N005/16.
-
- ☐ 15. [20020090660](#). 10 Jan 02. 11 Jul 02. Helicobacter pylori antigens in blood. Yi, Ching Sui A., et

al. 435/7.32; G01N033/554 G01N033/569.

-
- ☐ 16. 20020087205. 13 Jul 01. 04 Jul 02. Transcutaneous photodynamic treatment of targeted cells. Chen, James. 607/88; 606/9 A61B018/18 A61N001/00.
-
- ☐ 17. 6699722. 13 Apr 01; 02 Mar 04. Positive detection lateral-flow apparatus and method for small and large analytes. Bauer; Jeffrey S., et al. 436/518; 422/56 422/57 435/7.1 435/7.92 436/514 436/541. G01N033/543.
-
- ☐ 18. 6555390. 10 May 99; 29 Apr 03. Chromatographic assay or test device. Chandler; Howard Milne. 436/518; 422/56 422/58 422/61 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/4 435/7.1 435/803 435/805 435/810 435/970 436/169 436/501 436/514 436/524 436/527 436/528 436/530 436/538 436/541 436/807 436/810 436/814 436/823. G01N033/543.
-
- ☐ 19. 6544772. 08 Aug 00; 08 Apr 03. Polynucleotides, materials incorporating them, and methods for using them. Glenn; Matthew, et al. 435/252.3; 435/320.1 536/23.7. C12N001/21 C12N015/63 C12N015/31.
-
- ☐ 20. 6528321. 26 Jun 00; 04 Mar 03. Opposable-element chromatographic assay device for detection of analytes in whole blood samples. Fitzgerald; Daniel, et al. 436/514; 422/55 422/56 422/58 422/61 435/287.1 435/287.9 435/805 435/810 435/962 435/970 436/169 436/174 436/518 436/524 436/525 436/528 436/531 436/805 436/810. G01N033/53.
-
- ☐ 21. 6500629. 13 Sep 00; 31 Dec 02. Materials and methods for detection and quantitation of an analyte. Cleaver; Brian D., et al. 435/7.92; 422/101 422/102 422/55 422/56 422/57 422/58 422/59 422/60 422/61 422/70 435/188 435/28 435/4 435/5 435/6 435/7.1 435/7.21 435/810 436/507 436/513 436/518 436/531 436/548 436/808 436/810 436/814 436/818 436/826 530/300 530/350 536/23.4 53 6/23.7. G01N033/53.
-
- ☐ 22. 6476209. 28 Nov 00; 05 Nov 02. Polynucleotides, materials incorporating them, and methods for using them. Glenn; Matthew, et al. 536/23.1; 435/6 435/91.1 530/200 536/22.1. C07H021/02 C07H021/04 C12Q001/68 C12P019/34.
-
- ☐ 23. 6365198. 28 Jan 01; 02 Apr 02. Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids. Niazi; Sarfaraz K.. 424/725;. A01K065/00 A61K035/78.
-
- ☐ 24. 6248551. 23 Feb 98; 19 Jun 01. Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides. De Reuse; Hilde, et al. 435/18; 435/106 435/228 435/32 435/6 514/2 530/344 530/350. A61K039/02.
-
- ☐ 25. 6107464. 06 Oct 99; 22 Aug 00. iceA gene and related methods. Miller; Geraldine G., et al. 530/350; 424/185.1. C07K001/00 C07K014/00.
-
- ☐ 26. 6017767. 05 Jun 95; 25 Jan 00. Assay device. Chandler; Howard M.. 436/514; 422/56 422/57 422/58 422/61 435/287.7 435/287.9 435/288.4 435/288.5 435/7.1 435/7.2 435/7.9 435/7.93 435/7.94 435/7.95 435/969 435/970 435/973 436/518 436/524 436/807 436/809 436/810. G01N033/558 G01N033/543.
-
- ☐ 27. 6004354. 15 Apr 98; 21 Dec 99. IceA gene and related methods. Miller; Geraldine G., et al. 435/6; 435/7.32 514/44. C12N015/00.
-

- ☐ 28. 5998220. 10 Feb 94; 07 Dec 99. Opposable-element assay devices, kits, and methods employing them. Chandler; Howard M.. 436/514; 422/55 422/56 422/58 422/61 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/288.5 435/7.92 435/7.93 435/7.94 435/805 435/810 435/970 435/973 435/975 436/164 436/169 436/518 436/530 436/807 436/808 436/810. G01N033/558.
-
- ☐ 29. 5965458. 09 Apr 97; 12 Oct 99. Test strip, its production and use. Kouvonon; Ilkka Sakari, et al. 436/518; 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.9 435/7.32 435/7.35 435/805 435/810 435/970 435/973 436/169 436/510 436/514 436/530 436/531 436/533 436/534 436/536 436/65 436/805 436/810 436/818. G01N033/543 G01N033/558.
-
- ☐ 30. 5939252. 09 May 97; 17 Aug 99. Detachable-element assay device. Lennon; Donald J., et al. 435/4; 422/58 435/7.1 435/7.2 435/7.32 435/7.34 435/7.92 435/7.93 435/7.94 435/7.95 435/970 435/975 436/518 436/525 436/807 436/808 436/825. C12Q001/00 G01N033/543.
-
- ☐ 31. 5919463. 16 Oct 95; 06 Jul 99. Clostridium difficile toxins as mucosal adjuvants. Thomas, Jr.; William D., et al. 424/239.1; 424/184.1 424/192.1 424/234.1 424/236.1 424/247.1 424/278.1 424/94.6 514/2 530/300 530/350 530/825. A61K039/08 A61K038/46.
-
- ☐ 32. 5877028. 31 Mar 93; 02 Mar 99. Immunochromatographic assay device. Chandler; Howard M., et al. 436/514; 422/56 422/58 422/60 435/287.1 435/287.2 435/287.7 435/287.9 435/7.92 435/7.93 435/7.94 435/7.95 435/805 435/810 435/970 435/975 436/169 436/501 436/518 436/805 436/810. G01N033/558.
-
- ☐ 33. 5869345. 02 Jun 95; 09 Feb 99. Opposable-element assay device employing conductive barrier. Chandler; Howard M.. 436/514; 422/55 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/288.3 435/288.4 435/805 435/810 435/970 435/973 435/975 436/164 436/169 436/518 436/530 436/536 436/538 436/541 436/805 436/808 436/810. G01N033/543 G01N033/558.
-
- ☐ 34. 5846838. 18 Jun 97; 08 Dec 98. Opposable-element assay device employing conductive barrier. Chandler; Howard M.. 436/514; 422/55 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/805 435/810 435/970 435/973 435/975 436/169 436/518 436/530 436/805 436/808 436/810. G01N033/558 G01N033/543.
-
- ☐ 35. 5837240. 26 Aug 97; 17 Nov 98. Multimeric, recombinant urease vaccine. Lee; Cynthia K., et al. 424/94.6; 424/234.1 435/227 514/925 514/926 514/927. A61K038/46 A61K039/02 A61K039/106.
-
- ☐ 36. 5780278. 20 May 96; 14 Jul 98. IceA gene and related methods. Miller; Geraldine G., et al. 536/23.7; 435/6. C12N015/00.
-
- ☐ 37. 5712170. 14 Nov 94; 27 Jan 98. Test strip, its production and use. Kouvonon; Ilkka Sakari, et al. 436/518; 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.9 435/4 435/805 435/810 435/970 435/971 435/973 436/169 436/510 436/514 436/528 436/531 436/805 436/810. G01N033/543 G01N033/558.
-
- ☐ 38. 5607863. 07 Dec 93; 04 Mar 97. Barrier-controlled assay device. Chandler; Howard M.. 436/518; 422/104 422/56 422/57 422/58 422/61 435/7.92 435/7.93 435/7.94 435/805 435/969 435/970 436/165 436/170 436/514 436/810. G01N033/543 G01N033/558.
-
- ☐ 39. 5468648. 07 Dec 93; 21 Nov 95. Interrupted-flow assay device. Chandler; Howard M.. 436/518; 422/58 422/60 435/7.1 435/7.92 435/7.93 435/7.94 435/7.95 435/970 435/973 435/974

436/514 436/525 436/530 436/538 436/540 436/807 436/810. G01N033/543.

☐ 40. 5459041. 18 Feb 88; 17 Oct 95. Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection. Blaser; Martin J., et al. 435/7.21; 435/7.3 435/7.92 435/7.93 435/7.94 435/7.95 435/961 435/974 435/975 436/518 436/527 436/528 436/529 436/531 436/533 436/547 436/804 530/350 530/413 530/806 530/810 530/825. G01N033/53.

☐ 41. JP02002333447A. 10 May 01. 22 Nov 02. INSPECTION METHOD FOR DETERMINING INFECTION TO HELICOBACTER PYLORI. WAKASUGI, MASAHIKO, et al. G01N033/573; C07K016/40 C12N005/10 G01N033/569 G01N033/577.

☐ 42. WO003093818A2. 30 Apr 03. 13 Nov 03. METHOD FOR PRE-TREATING STOOL SAMPLES. WENGLER, GEORGE. G01N033/53;.

☐ 43. WO002088737A1. 23 Apr 02. 07 Nov 02. IMMUNOCHROMATOGRAPHIC TEST PIECE AND DIAGNOSIS KIT. NAKAYA, SEIGO, et al. G01N033/543; G01N033/569 G01N033/573.

☐ 44. WO000163285A2. 14 Feb 01. 30 Aug 01. METHOD FOR DETECTING *HELICOBACTER PYLORI* AND *HEILMANII* IN FECAL AND SALIVARY SPECIMEN AND BIOPSY MATERIAL. ARMBRUSTER, FRANZ PAUL, et al. G01N033/569;.

☐ 45. DE 10219741A. Pretreating fecal samples, useful for detecting *Helicobacter pylori* antigens, by releasing antigens from endogenous antibodies, to allow their immunochemical detection. WENGLER, G S, et al. C12Q001/04 G01N001/28 G01N033/53 G01N033/569.

☐ 46. WO2002102842A. Novel immunogenic Helicobacter species surface protein useful as diagnostic antigens in immunodiagnostic tests e.g. for diagnosing liver, bile tract pancreas and inflammatory bowel disease in humans and animals. LJUNG, A, et al. C07K014/195 C07K014/205 G01N033/569.

☐ 47. US20020182600A. Detecting an analyte e.g. cocaine involves conjugating the nucleounits to indicator for the analyte forming nucleounit indicator conjugate and detecting the analyte of interest using the nucleounit indicator conjugate in a buffer. SMITH, J V. C12Q001/68.

☐ 48. WO 200288737A. Immunochromatographic test pieces with antibody on laminate for color reaction in kits for detecting *Helicobacter pylori* infection using feces as specimen e.g. in diagnosis of gastric or duodenal ulcer, chronic gastritis or stomach cancer. HIRATA, H, et al. G01N033/543 G01N033/569 G01N033/573.

☐ 49. DE 10006432A. Method for detecting microbial antigens in feces and saliva, useful for diagnosis and monitoring of *Helicobacter pylori* infection, by double-antibody sandwich assay. ARMBRUSTER, F P, et al. G01N033/541 G01N033/543 G01N033/554 G01N033/569 G01N033/577 G01N033/58.

☐ 50. US 5607863A. Chromatographic device for specific binding assay - uses a barrier, having an aperture, to control delivery of sample and reagent, provides improved accuracy and precision. CHANDLER, H M. A61K000/00 G01N033/532 G01N033/543 G01N033/558 G01N033/58.

Generate Collection

Print

Terms	Documents
L8 same (hybridoma or monoclonal or mono-clonal or moab or mab or m-ab or mo-ab or antibodies or antibody)	50

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 2 through 50 of 50 returned.**

-
- ☐ 2. [20040077965](#). 13 Nov 02. 22 Apr 04. Method for diagnosis of helicobacter pylori infection. Hubbard, Todd W., et al. 600/532; 422/84 73/23.3 A61B005/08 G01N033/497 G01N031/00.
-
- ☐ 3. [20040044197](#). 27 Jun 03. 04 Mar 04. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy. Pandey, Ravindra K., et al. 540/140; C09B047/04.
-
- ☐ 4. [20040023316](#). 27 Apr 01. 05 Feb 04. New method for detecting acid-resistant microorganisms in the stool. Reiter, Christian, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 5. [20040019505](#). 21 Jul 03. 29 Jan 04. Personalized health communication system. Bowman, Bradley R., et al. 705/2; G06F017/60.
-
- ☐ 6. [20030224401](#). 19 Feb 03. 04 Dec 03. Proteins for helicobacter diagnosis. Barthold, Stephen, et al. 435/6; 435/227 435/252.3 435/320.1 435/69.3 435/7.32 530/388.26 536/23.2 C12Q001/68 G01N033/554 G01N033/569 C07H021/04 C12N009/78 C12P021/02 C12N001/21.
-
- ☐ 7. [20030148411](#). 22 Jan 03. 07 Aug 03. Method for detecting helicobacter pylori and heilmanii in fecal and salivary specimen and biopsy material. Armbruster, Franz Paul, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 8. [20030124633](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 9. [20030124632](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 10. [20030109813](#). 10 Dec 02. 12 Jun 03. Energy-activated targeted cancer therapy. Chen, James. 601/2; A61H001/00.
-
- ☐ 11. [20030104484](#). 31 Dec 02. 05 Jun 03. Materials and methods for detection and quantitation of an analyte. Cleaver, Brian D., et al. 435/7.1; G01N033/53.
-
- ☐ 12. [20020182600](#). 11 Apr 01. 05 Dec 02. Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques. Smith, Jack V.. 435/6; C12Q001/68.
-
- ☐ 13. [20020160428](#). 26 Apr 02. 31 Oct 02. Quantitative non-instrumental immunoassay and device using coloured particles. Sundrehagen, Erling. 435/7.9; 435/287.2 G01N033/53 G01N033/542 C12M001/34.
-
- ☐ 14. [20020142291](#). 13 Apr 01. 03 Oct 02. Positive detection lateral-flow apparatus and method for small and large analytes. Bauer, Jeffrey S., et al. 435/5; 435/287.2 435/345 435/7.1 436/518 C12M001/34 G01N033/543 C12Q001/70 G01N033/53 C12M003/00 C12N005/06 C12N005/16.
-
- ☐ 15. [20020090660](#). 10 Jan 02. 11 Jul 02. Helicobacter pylori antigens in blood. Yi, Ching Sui A., et

al. 435/7.32; G01N033/554 G01N033/569.

☐ 16. 20020087205. 13 Jul 01. 04 Jul 02. Transcutaneous photodynamic treatment of targeted cells. Chen, James. 607/88; 606/9 A61B018/18 A61N001/00.

☐ 17. 6699722. 13 Apr 01; 02 Mar 04. Positive detection lateral-flow apparatus and method for small and large analytes. Bauer; Jeffrey S., et al. 436/518; 422/56 422/57 435/7.1 435/7.92 436/514 436/541. G01N033/543.

☐ 18. 6555390. 10 May 99; 29 Apr 03. Chromatographic assay or test device. Chandler; Howard Milne. 436/518; 422/56 422/58 422/61 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/4 435/7.1 435/803 435/805 435/810 435/970 436/169 436/501 436/514 436/524 436/527 436/528 436/530 436/538 436/541 436/807 436/810 436/814 436/823. G01N033/543.

☐ 19. 6544772. 08 Aug 00; 08 Apr 03. Polynucleotides, materials incorporating them, and methods for using them. Glenn; Matthew, et al. 435/252.3; 435/320.1 536/23.7. C12N001/21 C12N015/63 C12N015/31.

☐ 20. 6528321. 26 Jun 00; 04 Mar 03. Opposable-element chromatographic assay device for detection of analytes in whole blood samples. Fitzgerald; Daniel, et al. 436/514; 422/55 422/56 422/58 422/61 435/287.1 435/287.9 435/805 435/810 435/962 435/970 436/169 436/174 436/518 436/524 436/525 436/528 436/531 436/805 436/810. G01N033/53.

☐ 21. 6500629. 13 Sep 00; 31 Dec 02. Materials and methods for detection and quantitation of an analyte. Cleaver; Brian D., et al. 435/7.92; 422/101 422/102 422/55 422/56 422/57 422/58 422/59 422/60 422/61 422/70 435/188 435/28 435/4 435/5 435/6 435/7.1 435/7.21 435/810 436/507 436/513 436/518 436/531 436/548 436/808 436/810 436/814 436/818 436/826 530/300 530/350 536/23.4 53 6/23.7. G01N033/53.

☐ 22. 6476209. 28 Nov 00; 05 Nov 02. Polynucleotides, materials incorporating them, and methods for using them. Glenn; Matthew, et al. 536/23.1; 435/6 435/91.1 530/200 536/22.1. C07H021/02 C07H021/04 C12Q001/68 C12P019/34.

☐ 23. 6365198. 28 Jan 01; 02 Apr 02. Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids. Niazi; Sarfaraz K.. 424/725; A01K065/00 A61K035/78.

☐ 24. 6248551. 23 Feb 98; 19 Jun 01. Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides. De Reuse; Hilde, et al. 435/18; 435/106 435/228 435/32 435/6 514/2 530/344 530/350. A61K039/02.

☐ 25. 6107464. 06 Oct 99; 22 Aug 00. iceA gene and related methods. Miller; Geraldine G., et al. 530/350; 424/185.1. C07K001/00 C07K014/00.

☐ 26. 6017767. 05 Jun 95; 25 Jan 00. Assay device. Chandler; Howard M.. 436/514; 422/56 422/57 422/58 422/61 435/287.7 435/287.9 435/288.4 435/288.5 435/7.1 435/7.2 435/7.9 435/7.93 435/7.94 435/7.95 435/969 435/970 435/973 436/518 436/524 436/807 436/809 436/810. G01N033/558 G01N033/543.

☐ 27. 6004354. 15 Apr 98; 21 Dec 99. IceA gene and related methods. Miller; Geraldine G., et al. 435/6; 435/7.32 514/44. C12N015/00.

28. 5998220. 10 Feb 94; 07 Dec 99. Opposable-element assay devices, kits, and methods employing them. Chandler; Howard M.. 436/514; 422/55 422/56 422/58 422/61 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/288.5 435/7.92 435/7.93 435/7.94 435/805 435/810 435/970 435/973 435/975 436/164 436/169 436/518 436/530 436/807 436/808 436/810. G01N033/558.
-
29. 5965458. 09 Apr 97; 12 Oct 99. Test strip, its production and use. Kouvonen; Ilkka Sakari, et al. 436/518; 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.9 435/7.32 435/7.35 435/805 435/810 435/970 435/973 436/169 436/510 436/514 436/530 436/531 436/533 436/534 436/536 436/65 436/805 436/810 436/818. G01N033/543 G01N033/558.
-
30. 5939252. 09 May 97; 17 Aug 99. Detachable-element assay device. Lennon; Donald J., et al. 435/4; 422/58 435/7.1 435/7.2 435/7.32 435/7.34 435/7.92 435/7.93 435/7.94 435/7.95 435/970 435/975 436/518 436/525 436/807 436/808 436/825. C12Q001/00 G01N033/543.
-
31. 5919463. 16 Oct 95; 06 Jul 99. Clostridium difficile toxins as mucosal adjuvants. Thomas, Jr.; William D., et al. 424/239.1; 424/184.1 424/192.1 424/234.1 424/236.1 424/247.1 424/278.1 424/94.6 514/2 530/300 530/350 530/825. A61K039/08 A61K038/46.
-
32. 5877028. 31 Mar 93; 02 Mar 99. Immunochromatographic assay device. Chandler; Howard M., et al. 436/514; 422/56 422/58 422/60 435/287.1 435/287.2 435/287.7 435/287.9 435/7.92 435/7.93 435/7.94 435/7.95 435/805 435/810 435/970 435/975 436/169 436/501 436/518 436/805 436/810. G01N033/558.
-
33. 5869345. 02 Jun 95; 09 Feb 99. Opposable-element assay device employing conductive barrier. Chandler; Howard M.. 436/514; 422/55 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/288.3 435/288.4 435/805 435/810 435/970 435/973 435/975 436/164 436/169 436/518 436/530 436/536 436/538 436/541 436/805 436/808 436/810. G01N033/543 G01N033/558.
-
34. 5846838. 18 Jun 97; 08 Dec 98. Opposable-element assay device employing conductive barrier. Chandler; Howard M.. 436/514; 422/55 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/805 435/810 435/970 435/973 435/975 436/169 436/518 436/530 436/805 436/808 436/810. G01N033/558 G01N033/543.
-
35. 5837240. 26 Aug 97; 17 Nov 98. Multimeric, recombinant urease vaccine. Lee; Cynthia K., et al. 424/94.6; 424/234.1 435/227 514/925 514/926 514/927. A61K038/46 A61K039/02 A61K039/106.
-
36. 5780278. 20 May 96; 14 Jul 98. IceA gene and related methods. Miller; Geraldine G., et al. 536/23.7; 435/6. C12N015/00.
-
37. 5712170. 14 Nov 94; 27 Jan 98. Test strip, its production and use. Kouvonen; Ilkka Sakari, et al. 436/518; 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.9 435/4 435/805 435/810 435/970 435/971 435/973 436/169 436/510 436/514 436/528 436/531 436/805 436/810. G01N033/543 G01N033/558.
-
38. 5607863. 07 Dec 93; 04 Mar 97. Barrier-controlled assay device. Chandler; Howard M.. 436/518; 422/104 422/56 422/57 422/58 422/61 435/7.92 435/7.93 435/7.94 435/805 435/969 435/970 436/165 436/170 436/514 436/810. G01N033/543 G01N033/558.
-
39. 5468648. 07 Dec 93; 21 Nov 95. Interrupted-flow assay device. Chandler; Howard M.. 436/518; 422/58 422/60 435/7.1 435/7.92 435/7.93 435/7.94 435/7.95 435/970 435/973 435/974

436/514 436/525 436/530 436/538 436/540 436/807 436/810. G01N033/543.

☐ 40. 5459041. 18 Feb 88; 17 Oct 95. *Campylobacter pylori* antigens and uses thereof for detection of *Campylobacter pylori* infection. Blaser; Martin J., et al. 435/7.21; 435/7.3 435/7.92 435/7.93 435/7.94 435/7.95 435/961 435/974 435/975 436/518 436/527 436/528 436/529 436/531 436/533 436/547 436/804 530/350 530/413 530/806 530/810 530/825. G01N033/53.

☐ 41. JP02002333447A. 10 May 01. 22 Nov 02. INSPECTION METHOD FOR DETERMINING INFECTION TO *HELICOBACTER PYLORI*. WAKASUGI, MASAHIKO, et al. G01N033/573; C07K016/40 C12N005/10 G01N033/569 G01N033/577.

☐ 42. WO003093818A2. 30 Apr 03. 13 Nov 03. METHOD FOR PRE-TREATING STOOL SAMPLES. WENGLER, GEORGE. G01N033/53;.

☐ 43. WO002088737A1. 23 Apr 02. 07 Nov 02. IMMUNOCHROMATOGRAPHIC TEST PIECE AND DIAGNOSIS KIT. NAKAYA, SEIGO, et al. G01N033/543; G01N033/569 G01N033/573.

☐ 44. WO000163285A2. 14 Feb 01. 30 Aug 01. METHOD FOR DETECTING *HELICOBACTER PYLORI* AND *HEILMANII* IN FECAL AND SALIVARY SPECIMEN AND BIOPSY MATERIAL. ARMBRUSTER, FRANZ PAUL, et al. G01N033/569;.

☐ 45. DE 10219741A. Pretreating fecal samples, useful for detecting *Helicobacter pylori* antigens, by releasing antigens from endogenous antibodies, to allow their immunochemical detection. WENGLER, G S, et al. C12Q001/04 G01N001/28 G01N033/53 G01N033/569.

☐ 46. WO2002102842A. Novel immunogenic *Helicobacter* species surface protein useful as diagnostic antigens in immunodiagnostic tests e.g. for diagnosing liver, bile tract pancreas and inflammatory bowel disease in humans and animals. LJUNG, A, et al. C07K014/195 C07K014/205 G01N033/569.

☐ 47. US20020182600A. Detecting an analyte e.g. cocaine involves conjugating the nucleounits to indicator for the analyte forming nucleounit indicator conjugate and detecting the analyte of interest using the nucleounit indicator conjugate in a buffer. SMITH, J V. C12Q001/68.

☐ 48. WO 200288737A. Immunochromatographic test pieces with antibody on laminate for color reaction in kits for detecting *Helicobacter pylori* infection using feces as specimen e.g. in diagnosis of gastric or duodenal ulcer, chronic gastritis or stomach cancer. HIRATA, H, et al. G01N033/543 G01N033/569 G01N033/573.

☐ 49. DE 10006432A. Method for detecting microbial antigens in feces and saliva, useful for diagnosis and monitoring of *Helicobacter pylori* infection, by double-antibody sandwich assay. ARMBRUSTER, F P, et al. G01N033/541 G01N033/543 G01N033/554 G01N033/569 G01N033/577 G01N033/58.

☐ 50. US 5607863A. Chromatographic device for specific binding assay - uses a barrier, having an aperture, to control delivery of sample and reagent, provides improved accuracy and precision. CHANDLER, H M. A61K000/00 G01N033/532 G01N033/543 G01N033/558 G01N033/58.

Generate Collection

Print

Terms	Documents
L8 same (hybridoma or monoclonal or mono-clonal or moab or mab or m-ab or mo-ab or antibodies or antibody)	50

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

First Hit**End of Result Set**

L10: Entry 50 of 50

File: DWPI

Feb 9, 2004

DERWENT-ACC-NO: 1995-224441

DERWENT-WEEK: 200413

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Chromatographic device for specific binding assay - uses a barrier, having an aperture, to control delivery of sample and reagent, provides improved accuracy and precision

Basic Abstract Text (2):

USE - The device is used to perform immunoassays, opt. with signal amplification, e.g. for detection of lipopolysaccharides, haemoglobin (in faeces), antibodies to Helicobacter pylori etc.. More generally any other specific binding assays (e.g. lectin or receptor plus ligand; enzyme plus inhibitor or substrate, complementary nucleic acids) can be done.

First Hit Fwd Refs

L10: Entry 25 of 50

File: USPT

Aug 22, 2000

DOCUMENT-IDENTIFIER: US 6107464 A

TITLE: iceA gene and related methods

Detailed Description Text (46):

The sample can be a fluid sample comprising any body fluid which would contain IceA, a H. pylori cell containing the antigen or an antibody against H. pylori, such as blood, plasma, serum, saliva, gastric juice, sputum, mucus, urine and stool. Tissue samples can include gastric or duodenal tissue.

First Hit Fwd Refs

End of Result Set

L5: Entry 3 of 3

File: USPT

Feb 10, 1998

DOCUMENT-IDENTIFIER: US 5716791 A

TITLE: Immunoassay for H. pylori in fecal specimensAbstract Text (1):

A process for the determination of H. pylori in a fecal specimen comprising (a) dispersing a fecal specimen suspected of carrying H. pylori in a sample diluent; (b) contacting the fecal specimen in the diluent with a first polyclonal antibody for H. pylori antigen to form a complex of the antibody and the antigen; (c) separating said specimen and said complex; (d) exposing the complex to a second polyclonal antibody for said antigen and a portion of the antibody reacting with said complex, one of said first and second antibody being bound to a solid carrier and the other being labeled with a detection agent; and (e) determining the amount of the labeled antibody and in turn determining the presence of H. pylori antigen in said fecal specimen.

Brief Summary Text (4):

Several major antigens have been identified and used in immunoassays in the detection of H. pylori antibodies. However, these assays have not exhibited the specificity and sensitivity that are desired in serodiagnosis. Newell, D. G., et al. Serodiant. Immunother. Infec. Dis., 3:1-6 (1989). One problem with of these immunoassays is cross-reactivity. Studies of the dominant antigens in H. pylori, in particular, the putative flagellar protein, which has a molecular weight of 60 Da, have shown that some of these antigen are not specific to H. pylori and also found in other bacteria such as C. jeuni and C. coli. A second problem that has been encountered in designing immunoassays for H. pylori is strain variation. Substantial differences in the antigens has been observed in different strains of H. pylori. These problems preclude designing an assay around the use of a single antigen. They also rule out the use of monoclonal antibodies. One approach that has been taken to improving the specificity and selectivity of antibody immunoassays for H. pylori has been to use a mixture of antigens from different H. pylori strains which mixture is enriched with certain antigen fragments. One ELISA which detects H. pylori antibodies in a blood sera is commercially available from Meridian Diagnostics. This assay uses a bacterial whole cell lysate as the antigen.

CLAIMS:

1. A process for the determination of H. pylori in a fecal specimen which comprises:

(a) dispersing a fecal specimen suspected of carrying H. pylori in a sample diluent; diluent;

(b) contacting the fecal specimen in the diluent with a first polyclonal antibody for H. pylori antigen to form a complex of the antibody and the antigen;

(c) separating said specimen and said complex;

(d) exposing the complex to a second polyclonal antibody for said antigen and a portion of the antibody reacting with said complex, one of said first and second

antibody being bound to a solid carrier and the other being labelled with a detection agent; and

(e) determining the amount of the labelled antibody and in turn determining the presence of H. pylori antigen in said fecal specimen.

5. The process of claim 1 wherein said polyclonal antibody is obtained by sensitizing an antibody-producing mammal with H. pylori cells.

6. The process of claim 4 wherein the sample diluent contains a protein selected from the group consisting of fecal bovine serum, normal goat serum, guinea pig serum, horse serum, casein, albumin, gelatin, and bovine serum albumin.

8. The process of claim 5 wherein the cells are cells from a plurality of H. pylori strains.

12. A process for the determination of H. pylori in a fecal specimen which comprises:

(a) dispersing a fecal specimen suspected of carrying H. pylori in a sample diluent; diluent;

(b) contacting the fecal specimen in the diluent with a first polyclonal antibody for H. pylori antigen bound to a solid carrier and a second labelled polyclonal antibody for H. pylori to form a complex of the antibodies and the antigen;

(c) separating said specimen and said complex;

(d) determining the amount of the labelled antibody and in turn determining the presence of H. pylori antigen in said fecal specimen.

13. A process for the determination of H. pylori in a fecal specimen which comprises:

(a) dispersing a fecal specimen suspected of carrying H. pylori in a sample diluent; diluent;

(b) contacting the fecal specimen in the diluent with a first polyclonal antibody for H. pylori antigen produced by a first antibody-producing species and bound to a solid carrier to form a complex of the antibody and the antigen;

(c) separating said specimen and said complex;

(d) contacting the antibody-antigen complex formed in step (b) with a primary polyclonal antibody for H. pylori antigen obtained from a second antibody-producing species to produce a antibody-antigen-antibody complex;

(e) removing the primary antibody not present in the complex from step (d);

(f) contacting the antibody-antigen-antibody complex formed in step (d) with a secondary antibody, said secondary antibody being an antibody for the second antibody-producing species, whereby said secondary antibody forms a complex with said antibody-antigen-antibody complex; and

(g) determining the presence of H. pylori antigen in said fecal specimen.

[Generate Collection](#)[Print](#)**Search Results - Record(s) 2 through 50 of 50 returned.**

-
- ☐ 2. [20040077965](#). 13 Nov 02. 22 Apr 04. Method for diagnosis of helicobacter pylori infection. Hubbard, Todd W., et al. 600/532; 422/84 73/23.3 A61B005/08 G01N033/497 G01N031/00.
-
- ☐ 3. [20040044197](#). 27 Jun 03. 04 Mar 04. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy. Pandey, Ravindra K., et al. 540/140; C09B047/04.
-
- ☐ 4. [20040023316](#). 27 Apr 01. 05 Feb 04. New method for detecting acid-resistant microorganisms in the stool. Reiter, Christian, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 5. [20040019505](#). 21 Jul 03. 29 Jan 04. Personalized health communication system. Bowman, Bradley R., et al. 705/2; G06F017/60.
-
- ☐ 6. [20030224401](#). 19 Feb 03. 04 Dec 03. Proteins for helicobacter diagnosis. Barthold, Stephen, et al. 435/6; 435/227 435/252.3 435/320.1 435/69.3 435/7.32 530/388.26 536/23.2 C12Q001/68 G01N033/554 G01N033/569 C07H021/04 C12N009/78 C12P021/02 C12N001/21.
-
- ☐ 7. [20030148411](#). 22 Jan 03. 07 Aug 03. Method for detecting helicobacter pylori and heilmanii in fecal and salivary specimen and biopsy material. Armbruster, Franz Paul, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 8. [20030124633](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 9. [20030124632](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 10. [20030109813](#). 10 Dec 02. 12 Jun 03. Energy-activated targeted cancer therapy. Chen, James. 601/2; A61H001/00.
-
- ☐ 11. [20030104484](#). 31 Dec 02. 05 Jun 03. Materials and methods for detection and quantitation of an analyte. Cleaver, Brian D., et al. 435/7.1; G01N033/53.
-
- ☐ 12. [20020182600](#). 11 Apr 01. 05 Dec 02. Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques. Smith, Jack V.. 435/6; C12Q001/68.
-
- ☐ 13. [20020160428](#). 26 Apr 02. 31 Oct 02. Quantitative non-instrumental immunoassay and device using coloured particles. Sundrehagen, Erling. 435/7.9; 435/287.2 G01N033/53 G01N033/542 C12M001/34.
-
- ☐ 14. [20020142291](#). 13 Apr 01. 03 Oct 02. Positive detection lateral-flow apparatus and method for small and large analytes. Bauer, Jeffrey S., et al. 435/5; 435/287.2 435/345 435/7.1 436/518 C12M001/34 G01N033/543 C12Q001/70 G01N033/53 C12M003/00 C12N005/06 C12N005/16.
-
- ☐ 15. [20020090660](#). 10 Jan 02. 11 Jul 02. Helicobacter pylori antigens in blood. Yi, Ching Sui A., et



(1) BUNDESREPUBLIK (2) **Offenlegungsschrift** (3) Int. Cl.⁷:
 DEUTSCHLAND **DE 100 06 432 A 1** G 01 N 33/569

 DEUTSCHES
 PATENT- UND
 MARKENAMT
 DE 100 06 432 A 1

(4) Aktenzeichen: 100 06 432.9
 (5) Anmeldetag: 14. 2. 2000
 (6) Offenlegungstag: 16. 8. 2001

(7) Anmelder: GANZIMMUN Institut für ganzheitliche Immunologie und Naturheilverfahren AG, 55128 Mainz, DE; Imundiagnostik AG, 64626 Bensheim, DE (8) Vertreter: Benedum Haseltine Lake Partners, 81669 München	(9) Erfinder: Ambruster, Franz-Paul, Dr., 64626 Bensheim, DE; Crevar, Katarina, 64832 Babenhausen, DE; Ruppert, Jane, 64686 Lautertal, DE
--	--

Die folgenden Angaben sind den vom Anmelder eingewichteten Unterlagen entnommen

- (10) Verfahren zum Nachweis von *Helicobacter pylori* in Stuhl- und Speichelproben
- (11) Verfahren und Testsystem zum Nachweis von *Helicobacter* und/oder *Campylobacter* in Stuhl-, Speichel- und Sekretproben durch einen Doppelantikörper-Sandwich-Bindungsassay, wobei mindestens zwei verschiedene Primärantikörper eingesetzt werden, von denen der erste *Helicobacter*- oder *Campylobacter*-Antigen erkennt und der zweite menschliches Immunglobulin A, bevorzugt sekretorisches Human-IgA und Human-IgA2. Der Sekundärantikörper ist markiert, bspw. mit Biotin, Fluorescein, alkalischer Phosphatase oder Meerrettichperoxidase. Der erste Primärantikörper ist bevorzugt eine Mischung verschiedener polyklonaler Antikörper gegen unterschiedliche *Helicobacter pylori* Stämme.

DE 100 06 432 A 1

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum
Internationales Büro



(41) Internationales Veröffentlichungsdatum
30. August 2001 (30.08.2001)

(10) Internationale Veröffentlichungsnummer
PCT WO 01/63285 A2

(51) Internationale Patentklassifikation: G01N 33/569

(74) Anwalt: BENEDIUM, Ulrich, Max; Haselmeier Lake Partners, Rosenheimer Strasse 30, 81669 München (DE).

(21) Internationales Aktenzeichen: PCT/EP01/01639

(22) Internationales Anmeldedatum:
14. Februar 2001 (14.02.2001)

(25) Erreichungssprache: Deutsch

(26) Veröffentlichungssprache: Deutsch

(31) Bestimmungsstaaten (national): AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SI, SG, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.

(30) Angaben zur Priorität:
100 06 432.9 14. Februar 2000 (14.02.2000) DE

(71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme von US): IMMUNDIAGNOSTIK AG [DE/DE]; Wissenschafts-Strasse 4, 64625 Bensheim (DE). GANZIMMUN AG [DE/DE]; Institut für ganzheitliche Immunologie und Naturhe, Alverhofen, Hans-Böckler-Strasse 109, 55128 Mainz (DE).

(34) Bestimmungsstaaten (regional): ARIPO-Paten (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), europäisches Patent (AM, AZ, BY, BG, KZ, MD, RU, TJ, TM), europäisches Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI-Patent (BF, BI, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Veröffentlicht:

— ohne internationalen Recherchenbericht und erneut zu veröffentlichen nach Erhalt des Berichts

(72) Erfinder; und
(73) Erfinder/Anmelder (nur für US): ARMBRUSTER, Franz, Paul [DE/DE]; Immunodiagnostik AG, Wissenschafts-Strasse 4, 64625 Bensheim (DE). CREVAR, Katarina [DE/DE]; Breslauer Strasse 9, 64832 Babenhausen (DE). RUPPERT, Janna [DE/DE]; Rönnerweg 3, 64682 Lautertal (DE).

Zur Erklärung der Zweibuchstaben-Codes, und der anderen Abkürzungen wird auf die Erklärungen ("Guidance Notes on Codes and Abbreviations") am Anfang jeder regulären Ausgabe der PCT-Gazette verwiesen.

(54) Title: METHOD FOR DETECTING *HELICOBACTER PYLORI* AND *HELIAMANI* IN FECAL AND SALIVARY SPECIMEN AND BIOPSY MATERIAL

(54) Bezeichnung: VERFAHREN ZUM NACHWEIS VON *HELICOBACTER PYLORI* UND *HELIAMANI* IN STUHL- UND SPEICHELPROBEN UND BIOPSIEMATERIAL

(57) Abstract: The invention relates to a method for detecting pathogenic organisms, especially *Helicobacter pylori* and *H. heilmannii*, in fecal, salivary and secretion specimen by a double antibody sandwich assay. The inventive method is characterized by dissolving or dispersing the specimen together with a pathogenic antigen in a buffer solution and contacting the buffer solution with a solid phase to which at least two primary antibodies are bound, one of which specifically binds to the pathogenic antigen and the other to human immunoglobulin A; washing the solid phase of non-specifically bound proteins and contacting the solid phase with a secondary antibody that specifically binds to the pathogenic antigen; and determining the amount of specifically bound secondary antibody.

(57) Zusammenfassung: Verfahren zum Nachweis von krankheitsverursachenden Organismen, insbesondere *Helicobacter pylori* und *H. heilmannii*, in Stuhl-, Speichel- und Sekretproben durch einen Doppelantikörper-Sandwich-Bindungsassay, gekennzeichnet durch Aufnehmen oder Dispergieren der Probe mit Erregersantigen in einer Pufferlösung und Zusammenbringen der Pufferlösung mit einer festen Phase, an der mindestens zwei primäre Antikörper gebunden sind, von denen einer Erregersantigen und der andere menschliches Immunglobulin-A spezifisch bindet, Waschen der festen Phase von nicht spezifisch gebundenen Proteinen und Zusammenbringen der festen Phase mit einem sekundären Antikörper, der spezifisch an Erregersantigen bindet, und Bestimmen der Menge an spezifisch gebundenem Sekundärantikörper.

WO 01/63285 A2

(12)特許協力条約に基づいて公開された国際出願

(19) 世界知的所有権機関
国際事務局(43) 国際公開日
2002 年 11 月 7 日 (07.11.2002)

PCT

(10) 国際公開番号
WO 02/088737 A1

- (51) 国際特許分類: G01N 33/543, 33/569, 33/573 [JP] 特 103-8330 東京都中央区日本橋室町 1 丁目 5 番 3 号 わかもと製薬株式会社内 Tokyo (JP)
- (21) 国際出願番号: PCT/JP02/04011
- (22) 国際出願日: 2002 年 4 月 23 日 (23.04.2002)
- (23) 国際出願の言語: 日本語
- (24) 国際公開の言語: 日本語
- (30) 優先権データ:
特願 2001-124885 2001 年 4 月 23 日 (23.04.2001) JP
- (71) 出願人 (米国を除く全ての指定国について): わかもと製薬株式会社 (WAKAMOTO PHARMACEUTICAL CO., LTD.) [JP] 特 103-8330 東京都中央区日本橋室町 1 丁目 5 番 3 号 Tokyo (JP)
- (72) 発明者: および
- (73) 発明者/出願人 (米国についてのみ): 中谷 清吾 (NAKAYA, Seigo) [JP] 特 103-8330 東京都中央区日本橋室町 1 丁目 5 番 3 号 わかもと製薬株式会社内 Tokyo (JP) 佐藤 匡史 (SATO, Masami) [JP] 特 103-8330 東京都中央区日本橋室町 1 丁目 5 番 3 号 わかもと製薬株式会社内 Tokyo (JP) 堀山 博文 (KAWAYAMA, Hirotami) [JP] 特 103-8330 東京都中央区日本橋室町 1 丁目 5 番 3 号 わかもと製薬株式会社内 Tokyo (JP) 平田 晴久 (HIRATA, Harekisa)
- (81) 指定国 (国内): AF, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LI, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) 指定国 (広域): ARPO 特許 (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), ユーラシア特許 (AM, AZ, BY, BG, KZ, MD, RU, TJ, TM), ユーロッパ特許 (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI 特許 (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG).
- (54) Title: IMMUNOCHROMATOGRAPHIC TEST PIECE AND DIAGNOSIS KIT
- (54) 発明の名称: イムノクロマトグラフィー試験片及び診断キット
- (57) Abstract: It is intended to provide an immunochromatographic test piece and a diagnosis kit whereby infection with *Helicobacter pylori* can be judged at a high sensitivity with the use of feces as specimens. An immunochromatographic test piece comprising a laminate composed of a rectangular antibody immobilized substrate which has, on its bottom end, a support holding a colored latex particle-labeled material and a liquid sample-absorbing support made of filter paper laminated thereon in the order from the bottom to the top, and on its top end, a water-absorbing support made of filter paper laminated thereon. In the antibody immobilized substrate, a monoclonal antibody undergoing an antigen-antibody reaction with native catalase of *H. pylori* is immobilized on a microcellulose sheet. In the support holding the colored latex particle-labeled material, nonwoven fabric is impregnated with a colored latex particle-labeled anti-*H. pylori* antibody wherein a monoclonal antibody undergoing an antigen-antibody reaction with native catalase of *H. pylori* is immobilized on colored latex particles.

(結果有)

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum
Internationales Büro



(43) Internationales Veröffentlichungsdatum
13. November 2003 (13.11.2003)

(10) Internationale Veröffentlichungsnummer
PCT WO 03/093818 A2

- (51) Internationale Patentklassifikation: G01N 3353 (74) Anwalt: SCHMITZ, Hans-Werner, Hoefel, Schmitz, Weber & Partner, Gabriel-Max-Str. 29, 81545 München (DE)
- (21) Internationales Aktenzeichen: PCT/EP0304571
- (22) Internationales Anmeldedatum: 30. April 2003 (30.04.2003) (31) Bestimmungsstaaten (national): BR, CA, CN, JP, US.
- (25) Einreichungssprache: Deutsch (34) Bestimmungsstaaten (regional): europäisches Patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR).
- (26) Veröffentlichungssprache: Deutsch Veröffentlicht: — ohne internationalen Recherchenbericht und erneut zu veröffentlichen nach Erhalt des Berichts
- (30) Angaben zur Priorität: 102 19 741.5 2. Mai 2002 (02.05.2002) DE
- (71) Anmelder und (72) Erfinder: WENGLER, George (AT/AT); Fischhof 30, A-4894 Oberhofen (AT).
- Zur Erklärung der Zweisprachigen-Codes und der anderen Abkürzungen wird auf die Erklärungen ("Guidance Notes on Codes and Abbreviations") am Anfang jeder regulären Ausgabe der PCT-Gazette verwiesen.



WO 03/093818 A2

(54) Title: METHOD FOR PRE-TREATING STOOL SAMPLES

(54) Bezeichnung: VERFAHREN ZUR VORBEHANDLUNG VON STUHLPROBEN

(57) Abstract: The invention relates to a method for pre-treating stool samples, whereby *Helicobacter pylori* antigens are separated from bonds comprising endogenous antibodies. Said pre-treatment is carried out before the assay of *Helicobacter pylori* antigens in the stool, using immunological techniques.

(57) Zusammenfassung: Die Erfindung betrifft ein Verfahren zur Vorbehandlung von Stuhlproben, um *Helicobacter pylori*-Antigene aus Bindungen mit endogenen Antikörpern abzuspalten, wobei besagte Vorbehandlung vor der Untersuchung auf *Helicobacter pylori*-Antigene im Stuhl mittels immunologischer Techniken durchgeführt wird.

First Hit Fwd Refs

L10: Entry 35 of 50

File: USPT

Nov 17, 1998

DOCUMENT-IDENTIFIER: US 5837240 A

TITLE: Multimeric, recombinant urease vaccine

Drawing Description Text (8):

FIGS. 5A, 5B and 5C are graphs showing the bacterial score versus the levels of serum IgA, serum IgG, and fecal IgA antibodies from mice immunized with recombinant H. pylori urease and cholera toxin (CT).

Drawing Description Text (9):

FIGS. 6A, 6B, 6C and 6D are graphs showing the bacterial score versus the levels of serum IgA, serum IgG, and fecal IgA antibodies from mice immunized with recombinant H. pylori urease and enterotoxigenic E. coli heat-labile toxin.

Detailed Description Text (56):

The effect of immunization route upon the anti-urease antibody response was examined in mice. Swiss-Webster mice were immunized four times at ten day intervals with either: 1) 200 .mu.g recombinant purified H. pylori urease with 10 .mu.g CT, either with or without NaHCO.sub.3, by oral administration; 2) 200 .mu.g recombinant purified H. pylori urease and 10 .mu.g CT with NaHCO.sub.3, by intragastric administration; or 3) 10 .mu.g recombinant purified H. pylori urease with Freund's adjuvant by subcutaneous administration. One week after the fourth vaccine dose, mucosal and serum antibody responses were examined by ELISA using microtiter plates coated with 0.5 .mu.g of native H. pylori urease. Serum samples were diluted 1:100 and assayed for urease-specific IgA and IgG. Fresh fecal pellets, extracted with a protease inhibitor buffer (PBS containing 5% non-fat dry milk, 0.2 .mu.g AEBSF, 1 .mu.g aprotinin per ml, and 10 .mu.M leupeptin), were examined for fecal anti-urease IgA antibody. In some experiments, fecal antibody values were normalized for total IgA content determined by ELISA, with urease-specific fecal IgA expressed in A.sub.405 units/mg total IgA in each sample. Saliva samples were collected after stimulation with pilocarpine under ketamine anesthesia, and tested for urease-specific IgA at a dilution of 1:5.

Detailed Description Text (97):

The role of anti-urease antibodies in Helicobacter therapy, i.e., the clearance of H. felis from infected mice, was examined by first infecting Balb/c mice with 10.sup.7 H. felis. Four weeks after infection, the mice were orally immunized with 200 .mu.g recombinant urease plus 10 .mu.g CT. Control mice were given 10 .mu.g CT only. Antigen was administered 4 times at one week intervals. Animals were sacrificed 4 and 10 weeks after the last immunization, and serum and fecal samples were collected for ELISA.

First Hit

Nov 22, 2002

TITLE: INSPECTION METHOD FOR DETERMINING INFECTION TO HELICOBACTER PYLORI

Abstract Text (2) :

SOLUTION: The inspection method comprises determining the infection to Helicobacter pylori by detecting the native catalase of Helicobacter pylori present in an alimentary canal excrement with a monoclonal antibody for the native catalase of Helicobacter pylori. The monoclonal antibody is the one produced by hybridoma 31A3 (FERM P-18329) and/or hybridoma 82A3 (FERM P-18328).

WEST Search History

Hide Items

Restore


Clear

Cancel

DATE: Thursday, May 27, 2004

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=USPT; PLUR=YES; OP=AND</i>	
<input type="checkbox"/>	L1	(fecal or feaces or faeces or feces or excrement or (intestinal near2 contents) or (gastric near2 contents) or waste).ti,ab,clm.	35121
<input type="checkbox"/>	L2	L1 and (pylori or helicobacter or pyloris or pyloridis or pylro or pyloris or hpylori or h-pylori or pylorum).ti,ab,clm.	8
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=AND</i>	
<input type="checkbox"/>	L3	(fecal or feaces or faeces or feces or excrement or (intestinal near2 contents) or (gastric near2 contents) or waste).ti,ab,clm.	379549
<input type="checkbox"/>	L4	L3 and (pylori or helicobacter or pyloris or pyloridis or pylro or pyloris or hpylori or h-pylori or pylorum).ti,ab,clm.	48
		<i>DB=USPT; PLUR=YES; OP=AND</i>	
<input type="checkbox"/>	L5	(l2 or l4) and (hybridoma or hybrid-oma or monoclonal or mono-clonal or clonal or moab or mab or scfv or humanized)	3

END OF SEARCH HISTORY



gelatin (jel'ă-tin)

A derived protein formed from the collagen of tissues by boiling in water; it swells up when put in cold water, but dissolves only in hot water; used as a hemostat, plasma substitute, and protein food adjunct in malnutrition.

[L. *gelo*, pp. *gelatus*, to freeze, congeal]

[Prev](#)

Generate Collection

Print

Search Results - Record(s) 1 through 12 of 12 returned.

- ☐ 1. [RE38088](#). 08 Feb 00; 22 Apr 03. Immunoassay for *H. Pylori* in fecal specimens. Larka; Christopher Vance, et al. 435/7.32; 435/12 435/252.1 435/6 436/66. G01N033/554 G01N033/569.
- ☐ 2. [5932430](#). 10 Mar 98; 03 Aug 99. Immunoassay for *H. pylori* in fecal specimens. Larka; Christopher Vance, et al. 435/7.32; 435/12 435/252.1 435/7.21 436/66. G01N033/554 G01N033/569.
- ☐ 3. [5871942](#). 21 Jul 97; 16 Feb 99. Immunoassay for *H. pylori* in fecal specimens. Larka; Christopher Vance, et al. 435/7.32; 435/252.1. G01N033/554 G01N033/569.
- ☐ 4. [5716791](#). 09 May 96; 10 Feb 98. Immunoassay for *H. pylori* in fecal specimens. Larka; Christopher Vance, et al. 435/7.32; 435/12 436/66. G01N033/554 G01N033/569.
- ☐ 5. [JP410010128A](#). 17 Mar 97. 16 Jan 98. IMMUNOASSAY OF *H. PYLORIC* BACTERIUM IN EXCREMENT SAMPLE. LARKA, CHRISTOPHER VANCE, et al. G01N033/569;.
- ☐ 6. [EP001156331A1](#). 06 Apr 01. 21 Nov 01. Immunoassay for *H. Pylori* in fecal specimens using genus specific monoclonal antibody. KOZAK, KENNETH JAMES. G01N033/569; G01N033/554.
- ☐ 7. [EP000806667A1](#). 08 May 97. 12 Nov 97. Immunoassay for *h. pylori* in fecal specimens. LARKA, CHRISTOPHER VANCE, et al. G01N033/569; G01N033/541 G01N033/535 A61K039/106.
- ☐ 8. [EP 1156331A](#). Determination of *Helicobacter pylori* in fecal specimen, comprises using a genus specific monoclonal antibody to *Helicobacter* or *Camplobacter* and *H. pylori* specific antibodies. KOZAK, K J. G01N033/554 G01N033/569.
- ☐ 9. [WO 200140801A](#). Diagnosing and treating an infant exhibiting or suffering from colic comprises testing and treating for infection with *Helicobacter pylori*. WILLIS, D H. G01N033/569.
- ☐ 10. [US 5932430A](#). Immunoassay for *Helicobacter pylori* in fecal specimens. KOZAK, K J, et al. G01N033/554 G01N033/569.
- ☐ 11. [US 5871942A](#). A process for detecting the presence of *Helicobacter pylori* in faecal samples - which comprises collecting a smear of a faeces on a substrate and contacting the smear with polyclonal antibodies. KOZAK, K J, et al. G01N033/554 G01N033/569.
- ☐ 12. [EP 806667A](#). Detection of *Helicobacter pylori* - by immunoassay for *H. pylori* antigen in faecal samples. KOZAK, K J, et al. A61K039/106 G01N033/53 G01N033/535 G01N033/541 G01N033/543 G01N033/554 G01N033/569.

Generate Collection

Print

Terms	Documents
L2 and (pylori or helicobacter or pylroi or pylrois or pyloris or	12

pylorum or pyloridis or hpylori)	
----------------------------------	--

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

First Hit

Generate Collection

L3: Entry 11 of 12

File: DWPI

Feb 16, 1999

DERWENT-ACC-NO: 1999-166634

DERWENT-WEEK: 199938

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: A process for detecting the presence of Helicobacter pylori in faecal samples
samples - which comprises collecting a smear of a faeces on a substrate and
contacting the smear with polyclonal antibodies

INVENTOR: KOZAK, K J; LARKA, C V ; YI, C S A

PRIORITY-DATA: 1997US-0897732 (July 21, 1997), 1996US-0647115 (May 9, 1996)

Search Selected

Search ALL

Clear

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> <u>US 5871942 A</u>	February 16, 1999		007	G01N033/554

INT-CL (IPC): G01 N 33/554; G01 N 33/569

[Generate Collection](#)[Print](#)**Search Results - Record(s) 2 through 50 of 50 returned.**

-
- ☐ 2. [20040077965](#). 13 Nov 02. 22 Apr 04. Method for diagnosis of helicobacter pylori infection. Hubbard, Todd W., et al. 600/532; 422/84 73/23.3 A61B005/08 G01N033/497 G01N031/00.
-
- ☐ 3. [20040044197](#). 27 Jun 03. 04 Mar 04. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy. Pandey, Ravindra K., et al. 540/140; C09B047/04.
-
- ☐ 4. [20040023316](#). 27 Apr 01. 05 Feb 04. New method for detecting acid-resistant microorganisms in the stool. Reiter, Christian, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 5. [20040019505](#). 21 Jul 03. 29 Jan 04. Personalized health communication system. Bowman, Bradley R., et al. 705/2; G06F017/60.
-
- ☐ 6. [20030224401](#). 19 Feb 03. 04 Dec 03. Proteins for helicobacter diagnosis. Barthold, Stephen, et al. 435/6; 435/227 435/252.3 435/320.1 435/69.3 435/7.32 530/388.26 536/23.2 C12Q001/68 G01N033/554 G01N033/569 C07H021/04 C12N009/78 C12P021/02 C12N001/21.
-
- ☐ 7. [20030148411](#). 22 Jan 03. 07 Aug 03. Method for detecting helicobacter pylori and heilmanii in fecal and salivary specimen and biopsy material. Armbruster, Franz Paul, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 8. [20030124633](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 9. [20030124632](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 10. [20030109813](#). 10 Dec 02. 12 Jun 03. Energy-activated targeted cancer therapy. Chen, James. 601/2; A61H001/00.
-
- ☐ 11. [20030104484](#). 31 Dec 02. 05 Jun 03. Materials and methods for detection and quantitation of an analyte. Cleaver, Brian D., et al. 435/7.1; G01N033/53.
-
- ☐ 12. [20020182600](#). 11 Apr 01. 05 Dec 02. Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques. Smith, Jack V.. 435/6; C12Q001/68.
-
- ☐ 13. [20020160428](#). 26 Apr 02. 31 Oct 02. Quantitative non-instrumental immunoassay and device using coloured particles. Sundrehagen, Erling. 435/7.9; 435/287.2 G01N033/53 G01N033/542 C12M001/34.
-
- ☐ 14. [20020142291](#). 13 Apr 01. 03 Oct 02. Positive detection lateral-flow apparatus and method for small and large analytes. Bauer, Jeffrey S., et al. 435/5; 435/287.2 435/345 435/7.1 436/518 C12M001/34 G01N033/543 C12Q001/70 G01N033/53 C12M003/00 C12N005/06 C12N005/16.
-
- ☐ 15. [20020090660](#). 10 Jan 02. 11 Jul 02. Helicobacter pylori antigens in blood. Yi, Ching Sui A., et

al. 435/7.32; G01N033/554 G01N033/569.

☐ 16. 20020087205. 13 Jul 01. 04 Jul 02. Transcutaneous photodynamic treatment of targeted cells. Chen, James. 607/88; 606/9 A61B018/18 A61N001/00.

☐ 17. 6699722. 13 Apr 01; 02 Mar 04. Positive detection lateral-flow apparatus and method for small and large analytes. Bauer; Jeffrey S., et al. 436/518; 422/56 422/57 435/7.1 435/7.92 436/514 436/541. G01N033/543.

☐ 18. 6555390. 10 May 99; 29 Apr 03. Chromatographic assay or test device. Chandler; Howard Milne. 436/518; 422/56 422/58 422/61 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/4 435/7.1 435/803 435/805 435/810 435/970 436/169 436/501 436/514 436/524 436/527 436/528 436/530 436/538 436/541 436/807 436/810 436/814 436/823. G01N033/543.

☐ 19. 6544772. 08 Aug 00; 08 Apr 03. Polynucleotides, materials incorporating them, and methods for using them. Glenn; Matthew, et al. 435/252.3; 435/320.1 536/23.7. C12N001/21 C12N015/63 C12N015/31.

☐ 20. 6528321. 26 Jun 00; 04 Mar 03. Opposable-element chromatographic assay device for detection of analytes in whole blood samples. Fitzgerald; Daniel, et al. 436/514; 422/55 422/56 422/58 422/61 435/287.1 435/287.9 435/805 435/810 435/962 435/970 436/169 436/174 436/518 436/524 436/525 436/528 436/531 436/805 436/810. G01N033/53.

☐ 21. 6500629. 13 Sep 00; 31 Dec 02. Materials and methods for detection and quantitation of an analyte. Cleaver; Brian D., et al. 435/7.92; 422/101 422/102 422/55 422/56 422/57 422/58 422/59 422/60 422/61 422/70 435/188 435/28 435/4 435/5 435/6 435/7.1 435/7.21 435/810 436/507 436/513 436/518 436/531 436/548 436/808 436/810 436/814 436/818 436/826 530/300 530/350 536/23.4 536/23.7. G01N033/53.

☐ 22. 6476209. 28 Nov 00; 05 Nov 02. Polynucleotides, materials incorporating them, and methods for using them. Glenn; Matthew, et al. 536/23.1; 435/6 435/91.1 530/200 536/22.1. C07H021/02 C07H021/04 C12Q001/68 C12P019/34.

☐ 23. 6365198. 28 Jan 01; 02 Apr 02. Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids. Niazi; Sarfaraz K.. 424/725;. A01K065/00 A61K035/78.

☐ 24. 6248551. 23 Feb 98; 19 Jun 01. Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides. De Reuse; Hilde, et al. 435/18; 435/106 435/228 435/32 435/6 514/2 530/344 530/350. A61K039/02.

☐ 25. 6107464. 06 Oct 99; 22 Aug 00. iceA gene and related methods. Miller; Geraldine G., et al. 530/350; 424/185.1. C07K001/00 C07K014/00.

☐ 26. 6017767. 05 Jun 95; 25 Jan 00. Assay device. Chandler; Howard M.. 436/514; 422/56 422/57 422/58 422/61 435/287.7 435/287.9 435/288.4 435/288.5 435/7.1 435/7.2 435/7.9 435/7.93 435/7.94 435/7.95 435/969 435/970 435/973 436/518 436/524 436/807 436/809 436/810. G01N033/558 G01N033/543.

☐ 27. 6004354. 15 Apr 98; 21 Dec 99. IceA gene and related methods. Miller; Geraldine G., et al. 435/6; 435/7.32 514/44. C12N015/00.

- ☐ 28. 5998220. 10 Feb 94; 07 Dec 99. Opposable-element assay devices, kits, and methods employing them. Chandler; Howard M.. 436/514; 422/55 422/56 422/58 422/61 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/288.5 435/7.92 435/7.93 435/7.94 435/805 435/810 435/970 435/973 435/975 436/164 436/169 436/518 436/530 436/807 436/808 436/810. G01N033/558.
-
- ☐ 29. 5965458. 09 Apr 97; 12 Oct 99. Test strip, its production and use. Kouvonen; Ilkka Sakari, et al. 436/518; 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.9 435/7.32 435/7.35 435/805 435/810 435/970 435/973 436/169 436/510 436/514 436/530 436/531 436/533 436/534 436/536 436/65 436/805 436/810 436/818. G01N033/543 G01N033/558.
-
- ☐ 30. 5939252. 09 May 97; 17 Aug 99. Detachable-element assay device. Lennon; Donald J., et al. 435/4; 422/58 435/7.1 435/7.2 435/7.32 435/7.34 435/7.92 435/7.93 435/7.94 435/7.95 435/970 435/975 436/518 436/525 436/807 436/808 436/825. C12Q001/00 G01N033/543.
-
- ☐ 31. 5919463. 16 Oct 95; 06 Jul 99. Clostridium difficile toxins as mucosal adjuvants. Thomas, Jr.; William D., et al. 424/239.1; 424/184.1 424/192.1 424/234.1 424/236.1 424/247.1 424/278.1 424/94.6 514/2 530/300 530/350 530/825. A61K039/08 A61K038/46.
-
- ☐ 32. 5877028. 31 Mar 93; 02 Mar 99. Immunochromatographic assay device. Chandler; Howard M., et al. 436/514; 422/56 422/58 422/60 435/287.1 435/287.2 435/287.7 435/287.9 435/7.92 435/7.93 435/7.94 435/7.95 435/805 435/810 435/970 435/975 436/169 436/501 436/518 436/805 436/810. G01N033/558.
-
- ☐ 33. 5869345. 02 Jun 95; 09 Feb 99. Opposable-element assay device employing conductive barrier. Chandler; Howard M.. 436/514; 422/55 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/288.3 435/288.4 435/805 435/810 435/970 435/973 435/975 436/164 436/169 436/518 436/530 436/536 436/538 436/541 436/805 436/808 436/810. G01N033/543 G01N033/558.
-
- ☐ 34. 5846838. 18 Jun 97; 08 Dec 98. Opposable-element assay device employing conductive barrier. Chandler; Howard M.. 436/514; 422/55 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/805 435/810 435/970 435/973 435/975 436/169 436/518 436/530 436/805 436/808 436/810. G01N033/558 G01N033/543.
-
- ☐ 35. 5837240. 26 Aug 97; 17 Nov 98. Multimeric, recombinant urease vaccine. Lee; Cynthia K., et al. 424/94.6; 424/234.1 435/227 514/925 514/926 514/927. A61K038/46 A61K039/02 A61K039/106.
-
- ☐ 36. 5780278. 20 May 96; 14 Jul 98. IceA gene and related methods. Miller; Geraldine G., et al. 536/23.7; 435/6. C12N015/00.
-
- ☐ 37. 5712170. 14 Nov 94; 27 Jan 98. Test strip, its production and use. Kouvonen; Ilkka Sakari, et al. 436/518; 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.9 435/4 435/805 435/810 435/970 435/971 435/973 436/169 436/510 436/514 436/528 436/531 436/805 436/810. G01N033/543 G01N033/558.
-
- ☐ 38. 5607863. 07 Dec 93; 04 Mar 97. Barrier-controlled assay device. Chandler; Howard M.. 436/518; 422/104 422/56 422/57 422/58 422/61 435/7.92 435/7.93 435/7.94 435/805 435/969 435/970 436/165 436/170 436/514 436/810. G01N033/543 G01N033/558.
-
- ☐ 39. 5468648. 07 Dec 93; 21 Nov 95. Interrupted-flow assay device. Chandler; Howard M.. 436/518; 422/58 422/60 435/7.1 435/7.92 435/7.93 435/7.94 435/7.95 435/970 435/973 435/974

436/514 436/525 436/530 436/538 436/540 436/807 436/810. G01N033/543.

☐ 40. 5459041. 18 Feb 88; 17 Oct 95. Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection. Blaser; Martin J., et al. 435/7.21; 435/7.3 435/7.92 435/7.93 435/7.94 435/7.95 435/961 435/974 435/975 436/518 436/527 436/528 436/529 436/531 436/533 436/547 436/804 530/350 530/413 530/806 530/810 530/825. G01N033/53.

☐ 41. JP02002333447A. 10 May 01. 22 Nov 02. INSPECTION METHOD FOR DETERMINING INFECTION TO HELICOBACTER PYLORI. WAKASUGI, MASAHIKO, et al. G01N033/573; C07K016/40 C12N005/10 G01N033/569 G01N033/577.

☐ 42. WO003093818A2. 30 Apr 03. 13 Nov 03. METHOD FOR PRE-TREATING STOOL SAMPLES. WENGLER, GEORGE. G01N033/53;.

☐ 43. WO002088737A1. 23 Apr 02. 07 Nov 02. IMMUNOCHROMATOGRAPHIC TEST PIECE AND DIAGNOSIS KIT. NAKAYA, SEIGO, et al. G01N033/543; G01N033/569 G01N033/573.

☐ 44. WO000163285A2. 14 Feb 01. 30 Aug 01. METHOD FOR DETECTING <i>HELICOBACTER PYLORI</i> AND <i>HEILMANII</i> IN FECAL AND SALIVARY SPECIMEN AND BIOPSY MATERIAL. ARMBRUSTER, FRANZ PAUL, et al. G01N033/569;.

☐ 45. DE 10219741A. Pretreating fecal samples, useful for detecting *Helicobacter pylori* antigens, by releasing antigens from endogenous antibodies, to allow their immunochemical detection. WENGLER, G S, et al. C12Q001/04 G01N001/28 G01N033/53 G01N033/569.

☐ 46. WO2002102842A. Novel immunogenic Helicobacter species surface protein useful as diagnostic antigens in immunodiagnostic tests e.g. for diagnosing liver, bile tract pancreas and inflammatory bowel disease in humans and animals. LJUNG, A, et al. C07K014/195 C07K014/205 G01N033/569.

☐ 47. US20020182600A. Detecting an analyte e.g. cocaine involves conjugating the nucleounits to indicator for the analyte forming nucleounit indicator conjugate and detecting the analyte of interest using the nucleounit indicator conjugate in a buffer. SMITH, J V. C12Q001/68.

☐ 48. WO 200288737A. Immunochromatographic test pieces with antibody on laminate for color reaction in kits for detecting *Helicobacter pylori* infection using feces as specimen e.g. in diagnosis of gastric or duodenal ulcer, chronic gastritis or stomach cancer. HIRATA, H, et al. G01N033/543 G01N033/569 G01N033/573.

☐ 49. DE 10006432A. Method for detecting microbial antigens in feces and saliva, useful for diagnosis and monitoring of *Helicobacter pylori* infection, by double-antibody sandwich assay. ARMBRUSTER, F P, et al. G01N033/541 G01N033/543 G01N033/554 G01N033/569 G01N033/577 G01N033/58.

☐ 50. US 5607863A. Chromatographic device for specific binding assay - uses a barrier, having an aperture, to control delivery of sample and reagent, provides improved accuracy and precision. CHANDLER, H M. A61K000/00 G01N033/532 G01N033/543 G01N033/558 G01N033/58.

Generate Collection

Print

Terms	Documents
L8 same (hybridoma or monoclonal or mono-clonal or moab or mab or m-ab or mo-ab or antibodies or antibody)	50

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 2 through 50 of 50 returned.**

-
- ☐ 2. [20040077965](#). 13 Nov 02. 22 Apr 04. Method for diagnosis of helicobacter pylori infection. Hubbard, Todd W., et al. 600/532; 422/84 73/23.3 A61B005/08 G01N033/497 G01N031/00.
-
- ☐ 3. [20040044197](#). 27 Jun 03. 04 Mar 04. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy. Pandey, Ravindra K., et al. 540/140; C09B047/04.
-
- ☐ 4. [20040023316](#). 27 Apr 01. 05 Feb 04. New method for detecting acid-resistant microorganisms in the stool. Reiter, Christian, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 5. [20040019505](#). 21 Jul 03. 29 Jan 04. Personalized health communication system. Bowman, Bradley R., et al. 705/2; G06F017/60.
-
- ☐ 6. [20030224401](#). 19 Feb 03. 04 Dec 03. Proteins for helicobacter diagnosis. Barthold, Stephen, et al. 435/6; 435/227 435/252.3 435/320.1 435/69.3 435/7.32 530/388.26 536/23.2 C12Q001/68 G01N033/554 G01N033/569 C07H021/04 C12N009/78 C12P021/02 C12N001/21.
-
- ☐ 7. [20030148411](#). 22 Jan 03. 07 Aug 03. Method for detecting helicobacter pylori and heilmanii in fecal and salivary specimen and biopsy material. Armbruster, Franz Paul, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 8. [20030124633](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 9. [20030124632](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 10. [20030109813](#). 10 Dec 02. 12 Jun 03. Energy-activated targeted cancer therapy. Chen, James. 601/2; A61H001/00.
-
- ☐ 11. [20030104484](#). 31 Dec 02. 05 Jun 03. Materials and methods for detection and quantitation of an analyte. Cleaver, Brian D., et al. 435/7.1; G01N033/53.
-
- ☐ 12. [20020182600](#). 11 Apr 01. 05 Dec 02. Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques. Smith, Jack V.. 435/6; C12Q001/68.
-
- ☐ 13. [20020160428](#). 26 Apr 02. 31 Oct 02. Quantitative non-instrumental immunoassay and device using coloured particles. Sundrehagen, Erling. 435/7.9; 435/287.2 G01N033/53 G01N033/542 C12M001/34.
-
- ☐ 14. [20020142291](#). 13 Apr 01. 03 Oct 02. Positive detection lateral-flow apparatus and method for small and large analytes. Bauer, Jeffrey S., et al. 435/5; 435/287.2 435/345 435/7.1 436/518 C12M001/34 G01N033/543 C12Q001/70 G01N033/53 C12M003/00 C12N005/06 C12N005/16.
-
- ☐ 15. [20020090660](#). 10 Jan 02. 11 Jul 02. Helicobacter pylori antigens in blood. Yi, Ching Sui A., et

al. 435/7.32; G01N033/554 G01N033/569.

☐ 16. 20020087205. 13 Jul 01; 04 Jul 02. Transcutaneous photodynamic treatment of targeted cells. Chen, James. 607/88; 606/9 A61B018/18 A61N001/00.

☐ 17. 6699722. 13 Apr 01; 02 Mar 04. Positive detection lateral-flow apparatus and method for small and large analytes. Bauer; Jeffrey S., et al. 436/518; 422/56 422/57 435/7.1 435/7.92 436/514 436/541. G01N033/543.

☐ 18. 6555390. 10 May 99; 29 Apr 03. Chromatographic assay or test device. Chandler; Howard Milne. 436/518; 422/56 422/58 422/61 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/4 435/7.1 435/803 435/805 435/810 435/970 436/169 436/501 436/514 436/524 436/527 436/528 436/530 436/538 436/541 436/807 436/810 436/814 436/823. G01N033/543.

☐ 19. 6544772. 08 Aug 00; 08 Apr 03. Polynucleotides, materials incorporating them, and methods for using them. Glenn; Matthew, et al. 435/252.3; 435/320.1 536/23.7. C12N001/21 C12N015/63 C12N015/31.

☐ 20. 6528321. 26 Jun 00; 04 Mar 03. Opposable-element chromatographic assay device for detection of analytes in whole blood samples. Fitzgerald; Daniel, et al. 436/514; 422/55 422/56 422/58 422/61 435/287.1 435/287.9 435/805 435/810 435/962 435/970 436/169 436/174 436/518 436/524 436/525 436/528 436/531 436/805 436/810. G01N033/53.

☐ 21. 6500629. 13 Sep 00; 31 Dec 02. Materials and methods for detection and quantitation of an analyte. Cleaver; Brian D., et al. 435/7.92; 422/101 422/102 422/55 422/56 422/57 422/58 422/59 422/60 422/61 422/70 435/188 435/28 435/4 435/5 435/6 435/7.1 435/7.21 435/810 436/507 436/513 436/518 436/531 436/548 436/808 436/810 436/814 436/818 436/826 530/300 530/350 536/23.4 53 6/23.7. G01N033/53.

☐ 22. 6476209. 28 Nov 00; 05 Nov 02. Polynucleotides, materials incorporating them, and methods for using them. Glenn; Matthew, et al. 536/23.1; 435/6 435/91.1 530/200 536/22.1. C07H021/02 C07H021/04 C12Q001/68 C12P019/34.

☐ 23. 6365198. 28 Jan 01; 02 Apr 02. Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids. Niazi; Sarfaraz K.. 424/725;. A01K065/00 A61K035/78.

☐ 24. 6248551. 23 Feb 98; 19 Jun 01. Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides. De Reuse; Hilde, et al. 435/18; 435/106 435/228 435/32 435/6 514/2 530/344 530/350. A61K039/02.

☐ 25. 6107464. 06 Oct 99; 22 Aug 00. iceA gene and related methods. Miller; Geraldine G., et al. 530/350; 424/185.1. C07K001/00 C07K014/00.

☐ 26. 6017767. 05 Jun 95; 25 Jan 00. Assay device. Chandler; Howard M.. 436/514; 422/56 422/57 422/58 422/61 435/287.7 435/287.9 435/288.4 435/288.5 435/7.1 435/7.2 435/7.9 435/7.93 435/7.94 435/7.95 435/969 435/970 435/973 436/518 436/524 436/807 436/809 436/810. G01N033/558 G01N033/543.

☐ 27. 6004354. 15 Apr 98; 21 Dec 99. IceA gene and related methods. Miller; Geraldine G., et al. 435/6; 435/7.32 514/44. C12N015/00.

- ☐ 28. 5998220. 10 Feb 94; 07 Dec 99. Opposable-element assay devices, kits, and methods employing them. Chandler; Howard M.. 436/514; 422/55 422/56 422/58 422/61 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/288.5 435/7.92 435/7.93 435/7.94 435/805 435/810 435/970 435/973 435/975 436/164 436/169 436/518 436/530 436/807 436/808 436/810. G01N033/558.
-
- ☐ 29. 5965458. 09 Apr 97; 12 Oct 99. Test strip, its production and use. Kouvonen; Ilkka Sakari, et al. 436/518; 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.9 435/7.32 435/7.35 435/805 435/810 435/970 435/973 436/169 436/510 436/514 436/530 436/531 436/533 436/534 436/536 436/65 436/805 436/810 436/818. G01N033/543 G01N033/558.
-
- ☐ 30. 5939252. 09 May 97; 17 Aug 99. Detachable-element assay device. Lennon; Donald J., et al. 435/4; 422/58 435/7.1 435/7.2 435/7.32 435/7.34 435/7.92 435/7.93 435/7.94 435/7.95 435/970 435/975 436/518 436/525 436/807 436/808 436/825. C12Q001/00 G01N033/543.
-
- ☐ 31. 5919463. 16 Oct 95; 06 Jul 99. Clostridium difficile toxins as mucosal adjuvants. Thomas, Jr.; William D., et al. 424/239.1; 424/184.1 424/192.1 424/234.1 424/236.1 424/247.1 424/278.1 424/94.6 514/2 530/300 530/350 530/825. A61K039/08 A61K038/46.
-
- ☐ 32. 5877028. 31 Mar 93; 02 Mar 99. Immunochromatographic assay device. Chandler; Howard M., et al. 436/514; 422/56 422/58 422/60 435/287.1 435/287.2 435/287.7 435/287.9 435/7.92 435/7.93 435/7.94 435/7.95 435/805 435/810 435/970 435/975 436/169 436/501 436/518 436/805 436/810. G01N033/558.
-
- ☐ 33. 5869345. 02 Jun 95; 09 Feb 99. Opposable-element assay device employing conductive barrier. Chandler; Howard M.. 436/514; 422/55 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/288.3 435/288.4 435/805 435/810 435/970 435/973 435/975 436/164 436/169 436/518 436/530 436/536 436/538 436/541 436/805 436/808 436/810. G01N033/543 G01N033/558.
-
- ☐ 34. 5846838. 18 Jun 97; 08 Dec 98. Opposable-element assay device employing conductive barrier. Chandler; Howard M.. 436/514; 422/55 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/805 435/810 435/970 435/973 435/975 436/169 436/518 436/530 436/805 436/808 436/810. G01N033/558 G01N033/543.
-
- ☐ 35. 5837240. 26 Aug 97; 17 Nov 98. Multimeric, recombinant urease vaccine. Lee; Cynthia K., et al. 424/94.6; 424/234.1 435/227 514/925 514/926 514/927. A61K038/46 A61K039/02 A61K039/106.
-
- ☐ 36. 5780278. 20 May 96; 14 Jul 98. IceA gene and related methods. Miller; Geraldine G., et al. 536/23.7; 435/6. C12N015/00.
-
- ☐ 37. 5712170. 14 Nov 94; 27 Jan 98. Test strip, its production and use. Kouvonen; Ilkka Sakari, et al. 436/518; 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.9 435/4 435/805 435/810 435/970 435/971 435/973 436/169 436/510 436/514 436/528 436/531 436/805 436/810. G01N033/543 G01N033/558.
-
- ☐ 38. 5607863. 07 Dec 93; 04 Mar 97. Barrier-controlled assay device. Chandler; Howard M.. 436/518; 422/104 422/56 422/57 422/58 422/61 435/7.92 435/7.93 435/7.94 435/805 435/969 435/970 436/165 436/170 436/514 436/810. G01N033/543 G01N033/558.
-
- ☐ 39. 5468648. 07 Dec 93; 21 Nov 95. Interrupted-flow assay device. Chandler; Howard M.. 436/518; 422/58 422/60 435/7.1 435/7.92 435/7.93 435/7.94 435/7.95 435/970 435/973 435/974

436/514 436/525 436/530 436/538 436/540 436/807 436/810. G01N033/543.

☐ 40. [5459041](#). 18 Feb 88; 17 Oct 95. Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection. Blaser; Martin J., et al. 435/7.21; 435/7.3 435/7.92 435/7.93 435/7.94 435/7.95 435/961 435/974 435/975 436/518 436/527 436/528 436/529 436/531 436/533 436/547 436/804 530/350 530/413 530/806 530/810 530/825. G01N033/53.

☐ 41. [JP02002333447A](#). 10 May 01. 22 Nov 02. INSPECTION METHOD FOR DETERMINING INFECTION TO HELICOBACTER PYLORI. WAKASUGI, MASAHIKO, et al. G01N033/573; C07K016/40 C12N005/10 G01N033/569 G01N033/577.

☐ 42. [WO003093818A2](#). 30 Apr 03. 13 Nov 03. METHOD FOR PRE-TREATING STOOL SAMPLES. WENGLER, GEORGE. G01N033/53;.

☐ 43. [WO002088737A1](#). 23 Apr 02. 07 Nov 02. IMMUNOCHROMATOGRAPHIC TEST PIECE AND DIAGNOSIS KIT. NAKAYA, SEIGO, et al. G01N033/543; G01N033/569 G01N033/573.

☐ 44. [WO000163285A2](#). 14 Feb 01. 30 Aug 01. METHOD FOR DETECTING *HELICOBACTER PYLORI* AND *HEILMANII* IN FECAL AND SALIVARY SPECIMEN AND BIOPSY MATERIAL. ARMBRUSTER, FRANZ PAUL, et al. G01N033/569;.

☐ 45. [DE 10219741A](#). Pretreating fecal samples, useful for detecting *Helicobacter pylori* antigens, by releasing antigens from endogenous antibodies, to allow their immunochemical detection. WENGLER, G S, et al. C12Q001/04 G01N001/28 G01N033/53 G01N033/569.

☐ 46. [WO2002102842A](#). Novel immunogenic Helicobacter species surface protein useful as diagnostic antigens in immunodiagnostic tests e.g. for diagnosing liver, bile tract pancreas and inflammatory bowel disease in humans and animals. LJUNG, A, et al. C07K014/195 C07K014/205 G01N033/569.

☐ 47. [US20020182600A](#). Detecting an analyte e.g. cocaine involves conjugating the nucleounits to indicator for the analyte forming nucleounit indicator conjugate and detecting the analyte of interest using the nucleounit indicator conjugate in a buffer. SMITH, J V. C12Q001/68.

☐ 48. [WO 200288737A](#). Immunochromatographic test pieces with antibody on laminate for color reaction in kits for detecting *Helicobacter pylori* infection using feces as specimen e.g. in diagnosis of gastric or duodenal ulcer, chronic gastritis or stomach cancer. HIRATA, H, et al. G01N033/543 G01N033/569 G01N033/573.

☐ 49. [DE 10006432A](#). Method for detecting microbial antigens in feces and saliva, useful for diagnosis and monitoring of *Helicobacter pylori* infection, by double-antibody sandwich assay. ARMBRUSTER, F P, et al. G01N033/541 G01N033/543 G01N033/554 G01N033/569 G01N033/577 G01N033/58.

☐ 50. [US 5607863A](#). Chromatographic device for specific binding assay - uses a barrier, having an aperture, to control delivery of sample and reagent, provides improved accuracy and precision. CHANDLER, H M. A61K000/00 G01N033/532 G01N033/543 G01N033/558 G01N033/58.

Generate Collection

Print

Terms	Documents
L8 same (hybridoma or monoclonal or mono-clonal or moab or mab or m-ab or mo-ab or antibodies or antibody)	50

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 2 through 50 of 50 returned.**

-
- ☐ 2. [20040077965](#). 13 Nov 02. 22 Apr 04. Method for diagnosis of helicobacter pylori infection. Hubbard, Todd W., et al. 600/532; 422/84 73/23.3 A61B005/08 G01N033/497 G01N031/00.
-
- ☐ 3. [20040044197](#). 27 Jun 03. 04 Mar 04. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy. Pandey, Ravindra K., et al. 540/140; C09B047/04.
-
- ☐ 4. [20040023316](#). 27 Apr 01. 05 Feb 04. New method for detecting acid-resistant microorganisms in the stool. Reiter, Christian, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 5. [20040019505](#). 21 Jul 03. 29 Jan 04. Personalized health communication system. Bowman, Bradley R., et al. 705/2; G06F017/60.
-
- ☐ 6. [20030224401](#). 19 Feb 03. 04 Dec 03. Proteins for helicobacter diagnosis. Barthold, Stephen, et al. 435/6; 435/227 435/252.3 435/320.1 435/69.3 435/7.32 530/388.26 536/23.2 C12Q001/68 G01N033/554 G01N033/569 C07H021/04 C12N009/78 C12P021/02 C12N001/21.
-
- ☐ 7. [20030148411](#). 22 Jan 03. 07 Aug 03. Method for detecting helicobacter pylori and heilmanii in fecal and salivary specimen and biopsy material. Armbruster, Franz Paul, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 8. [20030124633](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 9. [20030124632](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 10. [20030109813](#). 10 Dec 02. 12 Jun 03. Energy-activated targeted cancer therapy. Chen, James. 601/2; A61H001/00.
-
- ☐ 11. [20030104484](#). 31 Dec 02. 05 Jun 03. Materials and methods for detection and quantitation of an analyte. Cleaver, Brian D., et al. 435/7.1; G01N033/53.
-
- ☐ 12. [20020182600](#). 11 Apr 01. 05 Dec 02. Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques. Smith, Jack V.. 435/6; C12Q001/68.
-
- ☐ 13. [20020160428](#). 26 Apr 02. 31 Oct 02. Quantitative non-instrumental immunoassay and device using coloured particles. Sundrehagen, Erling. 435/7.9; 435/287.2 G01N033/53 G01N033/542 C12M001/34.
-
- ☐ 14. [20020142291](#). 13 Apr 01. 03 Oct 02. Positive detection lateral-flow apparatus and method for small and large analytes. Bauer, Jeffrey S., et al. 435/5; 435/287.2 435/345 435/7.1 436/518 C12M001/34 G01N033/543 C12Q001/70 G01N033/53 C12M003/00 C12N005/06 C12N005/16.
-
- ☐ 15. [20020090660](#). 10 Jan 02. 11 Jul 02. Helicobacter pylori antigens in blood. Yi, Ching Sui A., et

al. 435/7.32; G01N033/554 G01N033/569.

☐ 16. 20020087205. 13 Jul 01. 04 Jul 02. Transcutaneous photodynamic treatment of targeted cells. Chen, James. 607/88; 606/9 A61B018/18 A61N001/00.

☐ 17. 6699722. 13 Apr 01; 02 Mar 04. Positive detection lateral-flow apparatus and method for small and large analytes. Bauer; Jeffrey S., et al. 436/518; 422/56 422/57 435/7.1 435/7.92 436/514 436/541. G01N033/543.

☐ 18. 6555390. 10 May 99; 29 Apr 03. Chromatographic assay or test device. Chandler; Howard Milne. 436/518; 422/56 422/58 422/61 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/4 435/7.1 435/803 435/805 435/810 435/970 436/169 436/501 436/514 436/524 436/527 436/528 436/530 436/538 436/541 436/807 436/810 436/814 436/823. G01N033/543.

☐ 19. 6544772. 08 Aug 00; 08 Apr 03. Polynucleotides, materials incorporating them, and methods for using them. Glenn; Matthew, et al. 435/252.3; 435/320.1 536/23.7. C12N001/21 C12N015/63 C12N015/31.

☐ 20. 6528321. 26 Jun 00; 04 Mar 03. Opposable-element chromatographic assay device for detection of analytes in whole blood samples. Fitzgerald; Daniel, et al. 436/514; 422/55 422/56 422/58 422/61 435/287.1 435/287.9 435/805 435/810 435/962 435/970 436/169 436/174 436/518 436/524 436/525 436/528 436/531 436/805 436/810. G01N033/53.

☐ 21. 6500629. 13 Sep 00; 31 Dec 02. Materials and methods for detection and quantitation of an analyte. Cleaver; Brian D., et al. 435/7.92; 422/101 422/102 422/55 422/56 422/57 422/58 422/59 422/60 422/61 422/70 435/188 435/28 435/4 435/5 435/6 435/7.1 435/7.21 435/810 436/507 436/513 436/518 436/531 436/548 436/808 436/810 436/814 436/818 436/826 530/300 530/350 536/23.4 536/23.7. G01N033/53.

☐ 22. 6476209. 28 Nov 00; 05 Nov 02. Polynucleotides, materials incorporating them, and methods for using them. Glenn; Matthew, et al. 536/23.1; 435/6 435/91.1 530/200 536/22.1. C07H021/02 C07H021/04 C12Q001/68 C12P019/34.

☐ 23. 6365198. 28 Jan 01; 02 Apr 02. Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids. Niazi; Sarfaraz K.. 424/725; A01K065/00 A61K035/78.

☐ 24. 6248551. 23 Feb 98; 19 Jun 01. Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides. De Reuse; Hilde, et al. 435/18; 435/106 435/228 435/32 435/6 514/2 530/344 530/350. A61K039/02.

☐ 25. 6107464. 06 Oct 99; 22 Aug 00. iceA gene and related methods. Miller; Geraldine G., et al. 530/350; 424/185.1. C07K001/00 C07K014/00.

☐ 26. 6017767. 05 Jun 95; 25 Jan 00. Assay device. Chandler; Howard M.. 436/514; 422/56 422/57 422/58 422/61 435/287.7 435/287.9 435/288.4 435/288.5 435/7.1 435/7.2 435/7.9 435/7.93 435/7.94 435/7.95 435/969 435/970 435/973 436/518 436/524 436/807 436/809 436/810. G01N033/558 G01N033/543.

☐ 27. 6004354. 15 Apr 98; 21 Dec 99. IceA gene and related methods. Miller; Geraldine G., et al. 435/6; 435/7.32 514/44. C12N015/00.

- ☐ 28. 5998220. 10 Feb 94; 07 Dec 99. Opposable-element assay devices, kits, and methods employing them. Chandler; Howard M.. 436/514; 422/55 422/56 422/58 422/61 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/288.5 435/7.92 435/7.93 435/7.94 435/805 435/810 435/970 435/973 435/975 436/164 436/169 436/518 436/530 436/807 436/808 436/810. G01N033/558.
-
- ☐ 29. 5965458. 09 Apr 97; 12 Oct 99. Test strip, its production and use. Kouvonen; Ilkka Sakari, et al. 436/518; 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.9 435/7.32 435/7.35 435/805 435/810 435/970 435/973 436/169 436/510 436/514 436/530 436/531 436/533 436/534 436/536 436/65 436/805 436/810 436/818. G01N033/543 G01N033/558.
-
- ☐ 30. 5939252. 09 May 97; 17 Aug 99. Detachable-element assay device. Lennon; Donald J., et al. 435/4; 422/58 435/7.1 435/7.2 435/7.32 435/7.34 435/7.92 435/7.93 435/7.94 435/7.95 435/970 435/975 436/518 436/525 436/807 436/808 436/825. C12Q001/00 G01N033/543.
-
- ☐ 31. 5919463. 16 Oct 95; 06 Jul 99. Clostridium difficile toxins as mucosal adjuvants. Thomas, Jr.; William D., et al. 424/239.1; 424/184.1 424/192.1 424/234.1 424/236.1 424/247.1 424/278.1 424/94.6 514/2 530/300 530/350 530/825. A61K039/08 A61K038/46.
-
- ☐ 32. 5877028. 31 Mar 93; 02 Mar 99. Immunochromatographic assay device. Chandler; Howard M., et al. 436/514; 422/56 422/58 422/60 435/287.1 435/287.2 435/287.7 435/287.9 435/7.92 435/7.93 435/7.94 435/7.95 435/805 435/810 435/970 435/975 436/169 436/501 436/518 436/805 436/810. G01N033/558.
-
- ☐ 33. 5869345. 02 Jun 95; 09 Feb 99. Opposable-element assay device employing conductive barrier. Chandler; Howard M.. 436/514; 422/55 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/288.3 435/288.4 435/805 435/810 435/970 435/973 435/975 436/164 436/169 436/518 436/530 436/536 436/538 436/541 436/805 436/808 436/810. G01N033/543 G01N033/558.
-
- ☐ 34. 5846838. 18 Jun 97; 08 Dec 98. Opposable-element assay device employing conductive barrier. Chandler; Howard M.. 436/514; 422/55 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.8 435/287.9 435/805 435/810 435/970 435/973 435/975 436/169 436/518 436/530 436/805 436/808 436/810. G01N033/558 G01N033/543.
-
- ☐ 35. 5837240. 26 Aug 97; 17 Nov 98. Multimeric, recombinant urease vaccine. Lee; Cynthia K., et al. 424/94.6; 424/234.1 435/227 514/925 514/926 514/927. A61K038/46 A61K039/02 A61K039/106.
-
- ☐ 36. 5780278. 20 May 96; 14 Jul 98. IceA gene and related methods. Miller; Geraldine G., et al. 536/23.7; 435/6. C12N015/00.
-
- ☐ 37. 5712170. 14 Nov 94; 27 Jan 98. Test strip, its production and use. Kouvonen; Ilkka Sakari, et al. 436/518; 422/56 422/57 422/58 435/287.1 435/287.2 435/287.7 435/287.9 435/4 435/805 435/810 435/970 435/971 435/973 436/169 436/510 436/514 436/528 436/531 436/805 436/810. G01N033/543 G01N033/558.
-
- ☐ 38. 5607863. 07 Dec 93; 04 Mar 97. Barrier-controlled assay device. Chandler; Howard M.. 436/518; 422/104 422/56 422/57 422/58 422/61 435/7.92 435/7.93 435/7.94 435/805 435/969 435/970 436/165 436/170 436/514 436/810. G01N033/543 G01N033/558.
-
- ☐ 39. 5468648. 07 Dec 93; 21 Nov 95. Interrupted-flow assay device. Chandler; Howard M.. 436/518; 422/58 422/60 435/7.1 435/7.92 435/7.93 435/7.94 435/7.95 435/970 435/973 435/974

436/514 436/525 436/530 436/538 436/540 436/807 436/810. G01N033/543.

☐ 40. [5459041](#). 18 Feb 88; 17 Oct 95. Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection. Blaser; Martin J., et al. 435/7.21; 435/7.3 435/7.92 435/7.93 435/7.94 435/7.95 435/961 435/974 435/975 436/518 436/527 436/528 436/529 436/531 436/533 436/547 436/804 530/350 530/413 530/806 530/810 530/825. G01N033/53.

☐ 41. [JP02002333447A](#). 10 May 01. 22 Nov 02. INSPECTION METHOD FOR DETERMINING INFECTION TO HELICOBACTER PYLORI. WAKASUGI, MASAHICO, et al. G01N033/573; C07K016/40 C12N005/10 G01N033/569 G01N033/577.

☐ 42. [WO003093818A2](#). 30 Apr 03. 13 Nov 03. METHOD FOR PRE-TREATING STOOL SAMPLES. WENGLER, GEORGE. G01N033/53;.

☐ 43. [WO002088737A1](#). 23 Apr 02. 07 Nov 02. IMMUNOCHROMATOGRAPHIC TEST PIECE AND DIAGNOSIS KIT. NAKAYA, SEIGO, et al. G01N033/543; G01N033/569 G01N033/573.

☐ 44. [WO000163285A2](#). 14 Feb 01. 30 Aug 01. METHOD FOR DETECTING *HELICOBACTER PYLORI* AND *HEILMANII* IN FECAL AND SALIVARY SPECIMEN AND BIOPSY MATERIAL. ARMBRUSTER, FRANZ PAUL, et al. G01N033/569;.

☐ 45. [DE 10219741A](#). Pretreating fecal samples, useful for detecting *Helicobacter pylori* antigens, by releasing antigens from endogenous antibodies, to allow their immunochemical detection. WENGLER, G S, et al. C12Q001/04 G01N001/28 G01N033/53 G01N033/569.

☐ 46. [WO2002102842A](#). Novel immunogenic *Helicobacter* species surface protein useful as diagnostic antigens in immunodiagnostic tests e.g. for diagnosing liver, bile tract pancreas and inflammatory bowel disease in humans and animals. LJUNG, A, et al. C07K014/195 C07K014/205 G01N033/569.

☐ 47. [US20020182600A](#). Detecting an analyte e.g. cocaine involves conjugating the nucleounits to indicator for the analyte forming nucleounit indicator conjugate and detecting the analyte of interest using the nucleounit indicator conjugate in a buffer. SMITH, J V. C12Q001/68.

☐ 48. [WO 200288737A](#). Immunochromatographic test pieces with antibody on laminate for color reaction in kits for detecting *Helicobacter pylori* infection using feces as specimen e.g. in diagnosis of gastric or duodenal ulcer, chronic gastritis or stomach cancer. HIRATA, H, et al. G01N033/543 G01N033/569 G01N033/573.

☐ 49. [DE 10006432A](#). Method for detecting microbial antigens in feces and saliva, useful for diagnosis and monitoring of *Helicobacter pylori* infection, by double-antibody sandwich assay. ARMBRUSTER, F P, et al. G01N033/541 G01N033/543 G01N033/554 G01N033/569 G01N033/577 G01N033/58.

☐ 50. [US 5607863A](#). Chromatographic device for specific binding assay - uses a barrier, having an aperture, to control delivery of sample and reagent, provides improved accuracy and precision. CHANDLER, H M. A61K000/00 G01N033/532 G01N033/543 G01N033/558 G01N033/58.

Generate Collection

Print

Terms	Documents
L8 same (hybridoma or monoclonal or mono-clonal or moab or mab or m-ab or mo-ab or antibodies or antibody)	50

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

[Mark Patent](#)
[Mark Range](#)
[Mark Section](#)
 ◀ ◀ 42 of 50 ▶ ▶ ▶ ▶ [All Sections](#) ▼ ▶ ▶ [Print](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 2 through 50 of 50 returned.**

-
- ☐ 2. [20040077965](#). 13 Nov 02. 22 Apr 04. Method for diagnosis of helicobacter pylori infection. Hubbard, Todd W., et al. 600/532; 422/84 73/23.3 A61B005/08 G01N033/497 G01N031/00.
-
- ☐ 3. [20040044197](#). 27 Jun 03. 04 Mar 04. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy. Pandey, Ravindra K., et al. 540/140; C09B047/04.
-
- ☐ 4. [20040023316](#). 27 Apr 01. 05 Feb 04. New method for detecting acid-resistant microorganisms in the stool. Reiter, Christian, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 5. [20040019505](#). 21 Jul 03. 29 Jan 04. Personalized health communication system. Bowman, Bradley R., et al. 705/2; G06F017/60.
-
- ☐ 6. [20030224401](#). 19 Feb 03. 04 Dec 03. Proteins for helicobacter diagnosis. Barthold, Stephen, et al. 435/6; 435/227 435/252.3 435/320.1 435/69.3 435/7.32 530/388.26 536/23.2 C12Q001/68 G01N033/554 G01N033/569 C07H021/04 C12N009/78 C12P021/02 C12N001/21.
-
- ☐ 7. [20030148411](#). 22 Jan 03. 07 Aug 03. Method for detecting helicobacter pylori and heilmanii in fecal and salivary specimen and biopsy material. Armbruster, Franz Paul, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 8. [20030124633](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 9. [20030124632](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 10. [20030109813](#). 10 Dec 02. 12 Jun 03. Energy-activated targeted cancer therapy. Chen, James. 601/2; A61H001/00.
-
- ☐ 11. [20030104484](#). 31 Dec 02. 05 Jun 03. Materials and methods for detection and quantitation of an analyte. Cleaver, Brian D., et al. 435/7.1; G01N033/53.
-
- ☐ 12. [20020182600](#). 11 Apr 01. 05 Dec 02. Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques. Smith, Jack V.. 435/6; C12Q001/68.
-
- ☐ 13. [20020160428](#). 26 Apr 02. 31 Oct 02. Quantitative non-instrumental immunoassay and device using coloured particles. Sundrehagen, Erling. 435/7.9; 435/287.2 G01N033/53 G01N033/542 C12M001/34.
-
- ☐ 14. [20020142291](#). 13 Apr 01. 03 Oct 02. Positive detection lateral-flow apparatus and method for small and large analytes. Bauer, Jeffrey S., et al. 435/5; 435/287.2 435/345 435/7.1 436/518 C12M001/34 G01N033/543 C12Q001/70 G01N033/53 C12M003/00 C12N005/06 C12N005/16.
-
- ☐ 15. [20020090660](#). 10 Jan 02. 11 Jul 02. Helicobacter pylori antigens in blood. Yi, Ching Sui A., et

[Generate Collection](#)[Print](#)**Search Results - Record(s) 2 through 50 of 50 returned.**

-
- ☐ 2. [20040077965](#). 13 Nov 02. 22 Apr 04. Method for diagnosis of helicobacter pylori infection. Hubbard, Todd W., et al. 600/532; 422/84 73/23.3 A61B005/08 G01N033/497 G01N031/00.
-
- ☐ 3. [20040044197](#). 27 Jun 03. 04 Mar 04. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy. Pandey, Ravindra K., et al. 540/140; C09B047/04.
-
- ☐ 4. [20040023316](#). 27 Apr 01. 05 Feb 04. New method for detecting acid-resistant microorganisms in the stool. Reiter, Christian, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 5. [20040019505](#). 21 Jul 03. 29 Jan 04. Personalized health communication system. Bowman, Bradley R., et al. 705/2; G06F017/60.
-
- ☐ 6. [20030224401](#). 19 Feb 03. 04 Dec 03. Proteins for helicobacter diagnosis. Barthold, Stephen, et al. 435/6; 435/227 435/252.3 435/320.1 435/69.3 435/7.32 530/388.26 536/23.2 C12Q001/68 G01N033/554 G01N033/569 C07H021/04 C12N009/78 C12P021/02 C12N001/21.
-
- ☐ 7. [20030148411](#). 22 Jan 03. 07 Aug 03. Method for detecting helicobacter pylori and heilmanii in fecal and salivary specimen and biopsy material. Armbruster, Franz Paul, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 8. [20030124633](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 9. [20030124632](#). 10 Jun 02. 03 Jul 03. Diagnostic methods. Kleimola, Vesa, et al. 435/7.32; G01N033/554 G01N033/569.
-
- ☐ 10. [20030109813](#). 10 Dec 02. 12 Jun 03. Energy-activated targeted cancer therapy. Chen, James. 601/2; A61H001/00.
-
- ☐ 11. [20030104484](#). 31 Dec 02. 05 Jun 03. Materials and methods for detection and quantitation of an analyte. Cleaver, Brian D., et al. 435/7.1; G01N033/53.
-
- ☐ 12. [20020182600](#). 11 Apr 01. 05 Dec 02. Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques. Smith, Jack V.. 435/6; C12Q001/68.
-
- ☐ 13. [20020160428](#). 26 Apr 02. 31 Oct 02. Quantitative non-instrumental immunoassay and device using coloured particles. Sundrehagen, Erling. 435/7.9; 435/287.2 G01N033/53 G01N033/542 C12M001/34.
-
- ☐ 14. [20020142291](#). 13 Apr 01. 03 Oct 02. Positive detection lateral-flow apparatus and method for small and large analytes. Bauer, Jeffrey S., et al. 435/5; 435/287.2 435/345 435/7.1 436/518 C12M001/34 G01N033/543 C12Q001/70 G01N033/53 C12M003/00 C12N005/06 C12N005/16.
-
- ☐ 15. [20020090660](#). 10 Jan 02. 11 Jul 02. Helicobacter pylori antigens in blood. Yi, Ching Sui A., et